latanoprost profile

Latanoprost: A prostaglandin F analog used to treat OCULAR HYPERTENSION in patients with GLAUCOMA. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

latanoprost : A prostaglandin Falpha that is the isopropyl ester prodrug of latanoprost free acid. Used in the treatment of open-angle glaucoma and ocular hypertension. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	5311221
CHEMBL ID	1051
CHEBI ID	6384
SCHEMBL ID	24698
MeSH ID	M0195347

Synonym
CHEMBL1051
xa-41
latanoprost (isopropyl ester)
phxa-41
gtpl1961
ar-202
nova-21027
t-2345
phxa41
xa41
phxa34 [as 15(r,s)-isomer]
catioprost
l-ppds
xalatan
latanoprost [usan:inn:ban]
5-heptenoic acid, 7-(3,5-dihydroxy-2-(3-hydroxy-5-phenylpentyl)cyclopentyl)-, 1-methylethyl ester, (1r-(1-alpha(z),2-beta(r*),3-alpha,5-alpha))-
xa 41
MLS001424106
latanoprost
isopropyl (z)-7-((1r,2r,3r,5s)-3,5-dihydroxy-2-((3r)-3-hydroxy-5-phenylpentyl)cyclopentyl)-5-heptenoate
latanoprostum
isopropyl (5z,9alpha,11alpha,15r)-9,11,15-trihydroxy-17-phenyl-18,19,20-trinorprost-5-en-1-oate
phxa 41
CHEBI:6384 ,
smr000466354
MLS000759468
propan-2-yl (5z)-7-{(1r,2r,3r,5s)-3,5-dihydroxy-2-[(3r)-3-hydroxy-5-phenylpentyl]cyclopentyl}hept-5-enoate
DB00654
130209-82-4
xalatan (tn)
D00356
latanoprost (jan/usp/inn)
HMS2051H11
HMS2089J17
bdbm50240648
T2345 ,
propan-2-yl (z)-7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-[(3r)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate
A806039
(z)-7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-[(3r)-3-hydroxy-5-phenylpentyl]cyclopentyl]-5-heptenoic acid propan-2-yl ester
propan-2-yl (z)-7-[(1r,2r,3r,5s)-3,5-bis(oxidanyl)-2-[(3r)-3-oxidanyl-5-phenyl-pentyl]cyclopentyl]hept-5-enoate
NCGC00246969-01
unii-6z5b6hvf6o
6z5b6hvf6o ,
S4709
CCG-100946
latanoprost [mi]
isopropyl (z)-7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-[(3r)-3-hydroxy-5-phenylpentyl]cyclopentyl]-5-heptenoate
latanoprost [usp monograph]
iyuzeh
latanoprost [ep monograph]
latanoprost [inn]
latanoprost [usp-rs]
rocklatan component latanoprost
latanoprost component of rocklatan
latanoprost [mart.]
latanoprost [orange book]
latanoprost [who-dd]
xelpros
xalacom component latanoprost
5-heptenoic acid, 7-(3,5-dihydroxy-2-(3-hydroxy-5-phenylpentyl)cyclopentyl)-1-methylethyl ester, (1r-(1.alpha.(z),2.beta.(r*),3.alpha.,5.alpha.))-
latanoprost [vandf]
latanoprost [jan]
latanoprost [usan]
HY-B0577
AB00640005-04
NC00196
SCHEMBL24698
AB00640005-06
(z)-isopropyl 7-((1r,2r,3r,5s)-3,5-dihydroxy-2-((r)-3-hydroxy-5-phenylpentyl)cyclopentyl)hept-5-enoate
GGXICVAJURFBLW-CEYXHVGTSA-N
(5z)-7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-[(3r)-3-hydroxy-5-phenylpentyl]cyclopentyl]-5-heptanoic acid 1-methylethyl ester
unii-8s5fb3xxg8
AKOS024458331
L0262
tris(2,4-dimethylphenyl)phosphine-5,5',5-trisulfonic acid trisodium salt
mfcd00216074
DTXSID1041057 ,
J-005764
(1r,2r,3r,5s,3''r)-7-[3,5-dihydroxy-2-(3-hydroxy-5-phenyl-pentyl)-cyclopentyl]-hept-5-enoic acid isopropyl ester
SR-01000759428-4
sr-01000759428
latanoprost, united states pharmacopeia (usp) reference standard
propan-2-yl (5z)-7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-[(3r)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate
AS-75099
EX-A1770
HMS3715N22
8S5FB3XXG8 ,
155551-81-8
5-heptenoic acid, 7-(3,5-dihydroxy-2-(3-hydroxy-5-phenylpentyl)cyclopentyl)-, 1-methylethyl ester
latanoprost, (+/-)-
Q634959
AMY30089
NCGC00246969-06
5-heptenoic acid, 7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-[(3r)-3-hydroxy-5-phenylpentyl]cyclopentyl]-, 1-methylethyl ester, (5z)-
isopropyl (5z,9alpha,11alpha,15r)-9,11,15-trihydroxy-17-phenyl-18,19,20-trinor-prost-5-en-1-oate;xalatan
latanoprost pf
latanoprost (ep monograph)
propan-2-yl (5z)-7-((1r,2r,3r,5s)-3,5-dihydroxy-2-((3r)-3-hydroxy-5-phenylpentyl)cyclopentyl)hept-5-enoate
s01ee01
latanoprost (usp monograph)
dtxcid9021057
latanoprost (mart.)
latanoprost ophthalmic solution 0.005%
latanoprost (usp-rs)
EN300-21692769

Excerpt	Reference	Relevance
" The most significant ocular side effect was increased pigmentation of the iris observed in five and suspected in seven more latanoprost-treated eyes."	( Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Alm, A; Stjernschantz, J, 1995)	0.29
" Monotherapy with xalathane is safe sufficiently effective, and comparable to combined therapy with timolol and pilocarpine."	( [Xalathane: comparative assessment of efficacy and safety in hypotensive therapy of glaucoma]. Erichev, VP; Iakubova, LV, )	0.13
" No differences were observed between treatments in visual acuity, anterior segment findings, or adverse events."	( Efficacy and safety of timolol solution once daily vs timolol gel added to latanoprost. Day, DG; Dubiner, HB; Holmes, KT; Sharpe, ED; Stewart, JA; Stewart, WC, 1999)	0.3
" The most frequently reported adverse ocular events were mild conjunctival hyperemia and iris pigmentation."	( Efficacy and safety of latanoprost eye drops for glaucoma treatment: a 1-year study in Japan. Araie, M; Azuma, I; Kitazawa, Y; Masuda, K; Mishima, HK; Suzuki, M, )	0.13
" Patients who were treated for less than three months, who failed therapy due to ineffectiveness of the medicine or an adverse event also were included."	( Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical beta-adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension. Chopra, H; Day, DG; Holmes, KT; Kolker, AE; Konstas, AG; Lee, WH; Rieser, JC; Sharpe, ED; Stewart, WC, 2000)	0.31
" The majority of adverse events during both treatments were judged as mild."	( Efficacy and side effects of latanoprost monotherapy compared to adding dorzolamide to timolol in patients with glaucoma and ocular hypertension--a three-month randomised study. Spanish Latanoprost Study Group. García Sanchez, J, )	0.13
" Both treatment regimens were safe and well tolerated, with no significant between-group differences in reports of specific adverse events."	( Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost. Cooke, D; Dirks, M; DuBiner, H; Felix, C; Stewart, WC; VanDenburgh, AM, 2001)	0.31
"03% provided better diurnal IOP control than latanoprost and was safe and well tolerated in patients with ocular hypertension and glaucoma."	( Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost. Cooke, D; Dirks, M; DuBiner, H; Felix, C; Stewart, WC; VanDenburgh, AM, 2001)	0.31
" Safety and tolerability parameters included adverse events and quality-of-life measures (e."	( Effectiveness and safety of brimonidine as adjunctive therapy for patients with elevated intraocular pressure in a large, open-label community trial. Gornbein, JA; Lee, DA, 2001)	0.31
" The most severe adverse effects were one case of corneal punctate erosion and one case of cystoid macular oedema in a pseudophakic patient."	( Effect of 0.005% latanoprost once daily on intraocular pressure in glaucomatous patients not adequately controlled by beta-blockers twice daily: a 3-year follow-up. Experience and incidence of side effects in a prospective study on 76 patients. Antinozzi, P; Costagliola, C; Del Prete, A; Fusco, R; Mastropasqua, L; Parmeggiani, F; Verolino, M, 2002)	0.31
" The new formulation appears to be safe and does not demonstrate any more side effects than either of the components."	( The efficacy and safety of unfixed and fixed combinations of latanoprost and other antiglaucoma medications. Alm, A; Diestelhorst, M; Higginbotham, EJ; Pfeiffer, N; Rouland, JF, 2002)	0.31
" Adverse events were recorded at each visit."	( Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure. Feldman, RM; Sheu, WP; Shin, DH, 2004)	0.32
" Intraocular pressures and adverse events were recorded."	( A 5-year, multicenter, open-label, safety study of adjunctive latanoprost therapy for glaucoma. Alm, A; McDermott, J; Schoenfelder, J, 2004)	0.32
" Adverse event profiles were similar for patients with and without increased pigmentation."	( A 5-year, multicenter, open-label, safety study of adjunctive latanoprost therapy for glaucoma. Alm, A; McDermott, J; Schoenfelder, J, 2004)	0.32
"Latanoprost therapy is safe and well tolerated for long-term treatment of open-angle glaucoma."	( A 5-year, multicenter, open-label, safety study of adjunctive latanoprost therapy for glaucoma. Alm, A; McDermott, J; Schoenfelder, J, 2004)	0.32
" The most common reason to discontinue therapy was lack of efficacy (n = 70, 4%) and adverse event (n = 17, 1%)."	( Short term efficacy and safety in glaucoma patients changed to the latanoprost 0.005%/timolol maleate 0.5% fixed combination from monotherapies and adjunctive therapies. Beausencourt, E; Hamacher, T; Jütte, M; Lorger, C; Maier, H; Neff, HM; Schinzel, M; Schlaffer, G; Scholz, R; Schölzel-Klatt, A; Stewart, WC, 2004)	0.32
" Adverse events were recorded at each visit."	( Concomitant administration of travoprost and brinzolamide versus fixed latanoprost/timolol combined therapy: three-month comparison of efficacy and safety. Castillo, A; Fernandez-Vidal, A; Garcia-Feijoo, J; Garcia-Sanchez, J; Martinez-de-la-Casa, JM; Mendez-Hernandez, C, 2004)	0.32
" The most common adverse event with latanoprost was ocular allergy (1."	( Intraocular pressure, safety and quality of life in glaucoma patients switching to latanoprost from adjunctive and monotherapy treatments. Fuchs, M; Haverkamp, F; Stewart, WC; Wuensch, S, )	0.13
" The most common adverse event with LTFC was conjunctival hyperemia, which occurred in patients not previously treated with latanoprost therapy (N=16, 10%)."	( Intraocular pressure and safety in glaucoma patients switching to latanoprost/timolol maleate fixed combination from mono- and adjunctive therapies. Bányai, L; Blask, KD; Konstas, AG; Kozobolis, VP; Maloutas, S; Stewart, WC; Teus, MA; Trüb, PR; Tsironi, S; Väth, J, 2004)	0.32
" There were no clinically significant ocular or systemic adverse effects."	( Efficacy and safety of latanoprost for glaucoma treatment: a three-month multicentric study in India. Baskaran, M; Parikh, R; Prasad, KK; Sekhar, GC; Sood, D; Sood, NN; Thomas, R; Vijaya, L, 2005)	0.33
" The impact on cellular viability and apoptosis in the same cell line was evaluated, to address the possible proinflammatory and/or toxic origin of the most frequent clinical impairments induced by prostanoids (i."	( In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells. Baudouin, C; Brignole-Baudouin, F; Guenoun, JM; Pauly, A; Rat, P; Warnet, JM, 2005)	0.33
"TNFalpha induced or stimulated expression of the three inflammatory markers, whereas the PGF2alpha, latanoprost, travoprost, and bimatoprost solutions did not induce an increase in these markers and even produced a marked reduction of ICAM-1 and PECAM-1 expression in those solutions most concentrated in BAC, thus suggesting a toxic phenomenon in cellular membranes induced by the preservative rather than the medication itself."	( In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells. Baudouin, C; Brignole-Baudouin, F; Guenoun, JM; Pauly, A; Rat, P; Warnet, JM, 2005)	0.33
" The most important adverse events for the prostaglandin derivatives were conjunctival hyperemia, eyelashes pigmentation and growth, iris pigmentation."	( Comparative analysis of the efficacy and safety of latanoprost, travoprost and the fixed combination timolol-dorzolamide; a prospective, randomized, masked, cross-over design study. Antohi, I; Chiseliţă, D; Danielescu, C; Medvichi, R, 2005)	0.33
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."	( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004)	0.32
" Both volunteered and elicited reports of adverse events were collected; all patients who were randomized and received > or =1 dose of study drug were included in the safety analysis."	( A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension. Cunliffe, IA; Franks, WA; Renard, JP; Rojanapongpun, P, 2006)	0.33
" Adverse events related to therapy were mild in nature, and there were no statistically significant differences between the 2 treatment groups."	( A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension. Cunliffe, IA; Franks, WA; Renard, JP; Rojanapongpun, P, 2006)	0.33
" The purpose of the present work was to compare the stability, clinical efficacy, and adverse effect profile of this formulation with the innovator product."	( Comparison of the stability, efficacy, and adverse effect profile of the innovator 0.005% latanoprost ophthalmic solution and a novel cyclodextrin-containing formulation. Alarcon-Oceguera, F; Baiza-Duran, L; Beltran-Loustaunau, M; Castaneda-Hernandez, G; Cortez-Gastelum, M; Garcidueñas-Mejia, J; Gomez-Bastar, P; Gonzalez, JR; Jimenez-Roman, J; Korder-Ortega, V; Ortiz, M; Paczka-Zapata, J; Quintana-Hau, J; Tornero-Montaño, R; Torres-Segura, M; Velasco-Gallegos, G, 2007)	0.34
" There was no significant difference in incidence of conjunctival hyperemia or any other adverse events in both the groups."	( A randomized, crossover, open label pilot study to evaluate the efficacy and safety of Xalatan in comparison with generic Latanoprost (Latoprost) in subjects with primary open angle glaucoma or ocular hypertension. Baskaran, M; Desai, C; George, R; Lingam, V; Narayanaswamy, A; Neog, A; Rajadhyaksha, V, )	0.13
" Treatment-related adverse events were mild in both groups."	( A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. Andrew, R; Danesh-Meyer, H; Kozobolis, V; Melamed, S; Topouzis, F; Wells, AP; Wells, D; Wieland, H, )	0.13
"5% fixed combination ophthalmic solution is an effective treatment for reducing IOP and it is safe and well-tolerated in patients with OAG or OH."	( A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. Andrew, R; Danesh-Meyer, H; Kozobolis, V; Melamed, S; Topouzis, F; Wells, AP; Wells, D; Wieland, H, )	0.13
" Adverse effects were assessed and conjunctival hyperemia was graded using a standardized scale."	( Efficacy and safety of a systematic switch from latanoprost to travoprost in patients with glaucoma. Aung, T; Ho, CL; Hoh, ST; Istiantoro, VW; Kumar, RS; Oen, FT, )	0.13
" There were 116 predominantly mild, nonserious adverse events attributed to the study drugs, reported by 86 (24."	( Effectiveness and safety of dorzolamide-timolol alone or combined with latanoprost in open-angle glaucoma or ocular hypertension. Bastien, NR; Koulis, T; Lesk, MR; Sampalis, F; Sampalis, JS, 2008)	0.35
"In patients with primary open-angle glaucoma or ocular hypertension and elevated IOP while on monotherapy with latanoprost, switching to dorzolamide-timolol or combining dorzolamide-timolol with latanoprost are effective and safe treatment options for reducing IOP and achieving therapeutic response."	( Effectiveness and safety of dorzolamide-timolol alone or combined with latanoprost in open-angle glaucoma or ocular hypertension. Bastien, NR; Koulis, T; Lesk, MR; Sampalis, F; Sampalis, JS, 2008)	0.35
" As systemic adverse events, there was one instance of malar flushing after brinzolamide addition and episodes of chest discomfort after timolol addition in 1 patient."	( Comparison of ocular hypotensive effect and safety of brinzolamide and timolol added to latanoprost. Ito, K; Matsunaga, K; Miura, K; Okawa, C; Sugimoto, K; Uji, Y, )	0.13
"To investigate the incidence of latanoprost-related adverse events of the cornea, iris, and retina and the occurrence of hyperpigmentation."	( A 5-year, randomized, open-label safety study of latanoprost and usual care in patients with open-angle glaucoma or ocular hypertension. Goldberg, I; Li, XY; Paggiarino, D; Selaru, P, )	0.13
" Serious adverse drug reactions were reported in 17/3936 (0."	( A 5-year, randomized, open-label safety study of latanoprost and usual care in patients with open-angle glaucoma or ocular hypertension. Goldberg, I; Li, XY; Paggiarino, D; Selaru, P, )	0.13
"This 5-year study suggests that latanoprost as prescribed in 14 countries is a safe long-term treatment for patients with glaucoma and ocular hypertension."	( A 5-year, randomized, open-label safety study of latanoprost and usual care in patients with open-angle glaucoma or ocular hypertension. Goldberg, I; Li, XY; Paggiarino, D; Selaru, P, )	0.13
" There was no statistical difference for any individual adverse event between treatments (p>0."	( Comparison of daytime efficacy and safety of dorzolamide/timolol maleate fixed combination versus latanoprost. Ahmad, A; Mulaney, J; Sonty, S; Stewart, JA; Stewart, WC, )	0.13
"Latanoprost is safe and equally effective to a fixed combination of dorzolamide and timolol in the treatment of uveitic glaucoma."	( Efficacy and safety of latanoprost in eyes with uveitic glaucoma. Chalkidou, S; Georgopoulos, G; Halkiadakis, I; Kostakou, A; Markomichelakis, NN; Papakonstantinou, D, 2009)	0.35
"To document patient/physician perceptions of adverse effects and their relationship to medication changes among patients prescribed prostaglandin analogs."	( The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: changes in prescription patterns and patient persistence. Gelb, L; Hahn, SR; Kim, EE; Tan, H; Zimmerman, TJ, 2009)	0.35
" Frequency of adverse effects noted by physicians and associations with medication change decisions were examined in charted data."	( The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: changes in prescription patterns and patient persistence. Gelb, L; Hahn, SR; Kim, EE; Tan, H; Zimmerman, TJ, 2009)	0.35
" Adverse effects were the second most common reasons noted by physicians for switching medications after lack of efficacy (19% vs."	( The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: changes in prescription patterns and patient persistence. Gelb, L; Hahn, SR; Kim, EE; Tan, H; Zimmerman, TJ, 2009)	0.35
"Ocular adverse effects, particularly hyperemia, negatively affect patient continuation with therapy and switching."	( The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: changes in prescription patterns and patient persistence. Gelb, L; Hahn, SR; Kim, EE; Tan, H; Zimmerman, TJ, 2009)	0.35
" The cationic emulsion of latanoprost will most likely have fewer long-term adverse effects on the ocular surface than formulations containing toxic preservative BAC and may improve long-term tolerance over BAC-containing antiglaucomatous topical treatments."	( Comparison of the ocular tolerability of a latanoprost cationic emulsion versus conventional formulations of prostaglandins: an in vivo toxicity assay. Baudouin, C; Brignole-Baudouin, F; Faure, MO; Lambert, G; Liang, H, 2009)	0.35
" Adverse events were recorded at each visit."	( Efficacy and safety of fixed combinations of latanoprost/timolol and dorzolamide/timolol in open-angle glaucoma or ocular hypertension. Grunden, JW; Kwok, K; Miglior, S, 2010)	0.36
"Latanoprost, travoprost, and bimatoprost are prostaglandin or prostamide-type ocular hypotensive medications, all of which are effective and safe for lowering intraocular pressure (IOP)."	( Prostaglandin efficacy and safety study undertaken by race (the PRESSURE study). Ahmed, II; Birt, CM; Buys, YM; Trope, GE, 2010)	0.36
" Adverse events were recorded and ocular safety was evaluated."	( Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study. Pillunat, LE; Ropo, A; Uusitalo, H, 2010)	0.36
" Ocular and systemic adverse events were recorded."	( Five-year, multicenter safety study of fixed-combination latanoprost/timolol (Xalacom) for open-angle glaucoma and ocular hypertension. Alm, A; Grunden, JW; Kwok, KK, )	0.13
"1% experienced a serious adverse event."	( Five-year, multicenter safety study of fixed-combination latanoprost/timolol (Xalacom) for open-angle glaucoma and ocular hypertension. Alm, A; Grunden, JW; Kwok, KK, )	0.13
" The fixed combination is safe and well tolerated for long-term treatment in patients with open-angle glaucoma or ocular hypertension."	( Five-year, multicenter safety study of fixed-combination latanoprost/timolol (Xalacom) for open-angle glaucoma and ocular hypertension. Alm, A; Grunden, JW; Kwok, KK, )	0.13
" Its goal was to compare the UNILAT generic product (latanoprost 50 microg/ml, eye drops solution, Unimed Pharma) with XALATAN original product (latanoprost 50 microg/ml, eye drops solution, Pfizer) and to prove that UNILAT is as effective and safe as original product."	( [Clinical trial of the generic product UNILAT following its efficiency and safety in glaucoma and intraocular hypertension]. Jancus, V; Okkelová, J; Strmen, P; Tvrdonová, M, 2010)	0.36
" Bimatoprost treatment was safe and well tolerated."	( Efficacy and safety of switching from topical latanoprost to bimatoprost in patients with normal-tension glaucoma. Baba, T; Fujimura, T; Hirooka, K; Mizote, M; Sato, S; Shiraga, F; Tenkumo, K; Ueda, H, 2011)	0.37
" Ocular symptoms and adverse events were monitored."	( A 4-week, dose-ranging study comparing the efficacy, safety and tolerability of latanoprost 75, 100 and 125 μg/mL to latanoprost 50 μg/mL (xalatan) in the treatment of primary open-angle glaucoma and ocular hypertension. Eveleth, D; Starita, C; Tressler, C, 2012)	0.38
" Conjunctival hyperemia, the most commonly reported adverse event, occurred in 16."	( A 4-week, dose-ranging study comparing the efficacy, safety and tolerability of latanoprost 75, 100 and 125 μg/mL to latanoprost 50 μg/mL (xalatan) in the treatment of primary open-angle glaucoma and ocular hypertension. Eveleth, D; Starita, C; Tressler, C, 2012)	0.38
" The gastro-intestinal effects are among the most reported adverse effects upon topical application of PGAs."	( Possible mechanism for the gastro-intestinal adverse effects upon topical application of Prostaglandin F₂α analogs. Cai, S; Li, X; Liu, X; Yan, N; Zhou, X, 2013)	0.39
" The most frequent ocular adverse event, drug intolerance, was reported in 1 (0."	( Efficacy and safety of preservative-free latanoprost eyedrops, compared with BAK-preserved latanoprost in patients with ocular hypertension or glaucoma. Baudouin, C; Delval, L; Fekih, LE; Renault, D; Rouland, JF; Stalmans, I; Traverso, CE, 2013)	0.39
" Adverse reactions associated with latanoprost were mainly ocular in nature."	( Meta-analysis of the Efficacy and Safety of Latanoprost Monotherapy in Patients With Angle-closure Glaucoma. Chen, R; Ong, ML; Wang, NL; Yang, K; Zhan, SY; Zheng, Z, 2016)	0.43
"Both LT and TT are safe and effective for the treatment of OHT associated with uveitis and greater IOP reduction may be achieved by TT than by LT treatment."	( Evaluation of Efficacy and Safety of Latanoprost/Timolol versus Travoprost/Timolol Fixed Combinations for Ocular Hypertension Associated with Uveitis. Kanda, T; Mine, I; Sakurai, Y; Shibata, M; Taguchi, M; Takeuchi, M, 2017)	0.46
"Uveitis due to brimonidine is a rare adverse effect, but it must be known."	( Hypertensive acute granulomatous anterior uveitis as a side effect of topical brimonidine. Arciniegas-Perasso, CA; Clemente-Tomás, R; Duch-Samper, AM; García-Ibor, F; Hervás-Hernandis, JM; Ruiz-Del Río, N, 2018)	0.48
" Adverse reactions and dropouts were recorded."	( Short-term Efficacy and Safety of a Latanoprost/Carteolol Fixed Combination Switched From Concomitant Therapy to in Patients With Primary Open-angle Glaucoma or Ocular Hypertension. Inoue, K; Ishida, K; Iwasa, M; Shiokawa, M; Tomita, G, 2018)	0.48
", tafluprost/timolol (TAF/TIM) and latanoprost/carteolol (LAT/CAR), by determining their effects on intraocular pressure (IOP) in ocular normotensive monkeys and examining their toxic effects on ocular surface using human corneal epithelial cells."	( Efficacy and safety of the fixed combinations of tafluprost/timolol and latanoprost/carteolol. Akaishi, T; Fuwa, M; Kato, M; Mieda, M; Shimazaki, A; Taniguchi, T; Yamashita, N, 2019)	0.51
" All treatments had some common adverse ocular effects."	( Comparative evaluation of Latanoprostene Bunod, Timolol Maleate, and latanoprost Ophthalmic Solutions to assess their safety and efficacy in lowering intraocular pressure for the management of Open-Angle Glaucoma. Liao, Y; Nie, X; Wang, Y, 2020)	0.56
" Topical latanoprost added to therapeutic efficacy of topical betamethason and minoxidil in treating patchy AA, suggesting it being beneficial and safe adjuvant therapy and add to efficacy of topical treatments without any adverse effects."	( Comparison of efficacy, safety and satisfaction of latanoprost versus minoxidil, betamethasone and in combination in patients with alopecia areata: A blinded multiple group randomized controlled trial. Behrangi, E; Ghassemi, M; Goodarzi, A; Jafari, M; Yazdanian, N, 2022)	0.72
" A major challenge in the treatment is the occurrence of adverse events and poor adherence."	( The use of benzalkonium chloride in topical glaucoma treatment: An investigation of the efficacy and safety of benzalkonium chloride-preserved intraocular pressure-lowering eye drops and their effect on conjunctival goblet cells. Nagstrup, AH, 2023)	0.91

Excerpt	Reference	Relevance
" The elimination half-life of the acid of latanoprost was estimated to be 13."	( Pharmacokinetics of latanoprost in the cynomolgus monkey. 2nd communication: repeated topical administration on the eye. Byding, P; Sjöquist, B; Stjernschantz, J; Uhlin, A, 1999)	0.3
" The half-life of latanoprost acid in the aqueous humor was 2-3 hours."	( Ocular and systemic pharmacokinetics of latanoprost in humans. Sjöquist, B; Stjernschantz, J, 2002)	0.31
"Currently available latanoprost solutions with different preservatives showed sufficient intraocular concentration to activate the FP receptor, but different pharmacokinetic profiles of absorption or elimination."	( Pharmacokinetic Analysis of Intraocular Penetration of Latanoprost Solutions with Different Preservatives in Human Eyes. Aihara, M; Hara, T; Hisaka, A; Honjo, M; Okubo, M; Satake, S; Sekine, Y; Shimada, M, 2018)	0.48

Excerpt	Reference	Relevance
"Once-daily latanoprost treatment provides uniform circadian (around-the-clock) IOP reduction by itself, or in combination with timolol."	( Around-the-clock intraocular pressure reduction with once-daily application of latanoprost by itself or in combination with timolol. Bito, LZ; Gaygi, Z; Nagy, ZT; Rácz, P; Ruzsonyi, MR, 1996)	0.29
"5% alone or combined with latanoprost in reducing IOP in a real-world setting."	( Effectiveness and safety of dorzolamide-timolol alone or combined with latanoprost in open-angle glaucoma or ocular hypertension. Bastien, NR; Koulis, T; Lesk, MR; Sampalis, F; Sampalis, JS, 2008)	0.35
" However, no studies have evaluated ripasudil combined with β-blockers and prostaglandin analogues."	( Additive Intraocular Pressure-Lowering Effects of the Rho Kinase Inhibitor Ripasudil (K-115) Combined With Timolol or Latanoprost: A Report of 2 Randomized Clinical Trials. Abe, H; Araie, M; Inoue, T; Kuwayama, Y; Suganami, H; Tanihara, H; Yamamoto, T, 2015)	0.42
"These clinical trials found additive IOP-lowering effects of ripasudil from placebo at trough and peak levels in combination with timolol and at peak level in combination with latanoprost."	( Additive Intraocular Pressure-Lowering Effects of the Rho Kinase Inhibitor Ripasudil (K-115) Combined With Timolol or Latanoprost: A Report of 2 Randomized Clinical Trials. Abe, H; Araie, M; Inoue, T; Kuwayama, Y; Suganami, H; Tanihara, H; Yamamoto, T, 2015)	0.42
"To examine the relevance of concentration of benzalkonium chloride (BAK) on the cornea, we investigated the effects of latanoprost containing BAK alone and in combination with other antiglaucoma drug classes on corneal epithelium in vitro in a cultured rabbit corneal cell line (SIRC) and in vivo, using a corneal resistance device (CRD)."	( In vitro and in vivo corneal effects of latanoprost combined with brimonidine, timolol, dorzolamide, or brinzolamide. Fukuda, M; Sasaki, H; Shibata, N; Shibata, S; Shibata, T; Sugiyama, K; Takeda, N, 2016)	0.43
" In this pilot (24 patients) left-right comparative study we addressed efficiency of prostaglandin F2α analogue latanoprost versus tacrolimus when combined with narrow-band ultraviolet B and microneedling in repigmentation of nonsegmental vitiligo lesions."	( A pilot comparative study of topical latanoprost and tacrolimus in combination with narrow-band ultraviolet B phototherapy and microneedling for the treatment of nonsegmental vitiligo. Korobko, IV; Lomonosov, KM, 2016)	0.43
" This study was designed to assess the therapeutic efficacy of microneedling in combination with NB-UVB phototherapy versus their combination with latanoprost in vitiligo."	( A comparative study of combined microneedling and narrowband ultraviolet B phototherapy versus their combination with topical latanoprost in the treatment of vitiligo. Doghaim, NN; Ghaly, NR; Lotfy, SS; Neinaa, YME, 2021)	0.62
"To explore the curative effect of nimodipine combined with latanoprost in the treatment of open-angle glaucoma and its effect on ocular hemodynamics and visual field defects."	( Efficacy of Nimodipine Combined with Latanoprost in Treating Open-Angle Glaucoma and Its Influence on Ocular Hemodynamics and Visual Field Defects. Duan, HP; Liu, R, 2022)	0.72
" According to different treatment plans, the patients were divided into two groups: an observation group (n = 46) treated with nimodipine combined with latanoprost, and a control group (n = 41) treated by latanoprost monotherapy."	( Efficacy of Nimodipine Combined with Latanoprost in Treating Open-Angle Glaucoma and Its Influence on Ocular Hemodynamics and Visual Field Defects. Duan, HP; Liu, R, 2022)	0.72
"Nimodipine combined with latanoprost eye drops is effective in the treatment of primary open-angle glaucoma, which could effectively improve the ocular hemodynamics and visual field defects of patients with fewer adverse reactions and higher safety."	( Efficacy of Nimodipine Combined with Latanoprost in Treating Open-Angle Glaucoma and Its Influence on Ocular Hemodynamics and Visual Field Defects. Duan, HP; Liu, R, 2022)	0.72

Excerpt	Reference	Relevance
"Latanoprost (13,14-dihydro-15(R)-17-phenyl-18,19,20-trinor-PGF2a isopropyl ester, CAS 130209-82-4 PhXA41, Xalatan) is an antiglaucoma prodrug which enhances the bioavailability of the drug into the eye compared to the corresponding acid."	( Pharmacokinetics of latanoprost in the cynomolgus monkey. 2nd communication: repeated topical administration on the eye. Byding, P; Sjöquist, B; Stjernschantz, J; Uhlin, A, 1999)	0.3
" The absorption rate of latanoprost and timolol into the aqueous humor was similar after administration of the FC compared to the two drugs given separately."	( Bioavailability in the human eye of a fixed combination of latanoprost and timolol compared to monotherapy. Calissendorff, B; Grunge-Lowerud, A; Högberg, G; Sjöquist, B, 2002)	0.31
" These findings may be valuable in developing formulation strategies to optimize ocular bioavailability of topically administered ocular agents."	( Expression of multidrug resistance associated protein 5 (MRP5) on cornea and its role in drug efflux. Herndon, BL; Karla, PK; Mitra, A; Pal, D; Quinn, TL; Thomas, P, 2009)	0.35
"The differences in permeability and bioavailability between the 3 ophthalmic latanoprost formulations are attributable to the differences in their composition."	( Does preservative content affect drug permeability? The permeability analysis in vitro of 3 ophthalmic Latanoprost formulations in a human epithelial cell culture model. Antonik, J; Cisek, A; Romaniuk, D; Romaniuk, W; Smagur, J, )	0.13
"2-fold) and bioavailability (2."	( Co-delivery of latanoprost and timolol from micelles-laden contact lenses for the treatment of glaucoma. Bu, R; Feng, S; Ge, Y; Gou, J; He, H; Tang, X; Wang, J; Xu, J; Yin, T; Zhang, A; Zhang, Y, 2019)	0.51
"Anti-glaucoma latanoprost-loaded ocular implants provide prolonged delivery and enhanced bioavailability relative to the conventional eye drops."	( Latanoprost Quantification in Ocular Implants and Tissues: HPLC-Fluorescence vs HPLC-UV. Jirjees, F; Jones, D; Sheshala, R; Singh, TRR; Soliman, K; Sonawane, R; Wang, Y, 2021)	0.62

Excerpt	Relevance	Reference
" Dosing once daily was at least as effective as twice daily."	( Intraocular pressure-reducing effect of PhXA41 in ocular hypertension. Comparison of dose regimens. Hitchings, RA; Nagasubramanian, S; Sheth, GP; Stjernschantz, J, 1993)	0.29
"To establish the dose-response relationship for the effect on intraocular pressure (IOP) and side effects during long-term treatment of patients with ocular hypertension with the prostaglandin F2 alpha (PGF2 alpha) analog PhXA41."	( Intraocular pressure-reducing effect of PhXA41 in patients with increased eye pressure. A one-month study. Airaksinen, J; Alm, A; Mandahl, A; Marsk, A; Resul, B; Stjernschantz, J; Törnquist, P; Tuulonen, A; Villumsen, J, 1993)	0.29
"The three concentrations of PhXA41 reduced the average IOP between 31% and 38% during the second day of treatment, with only a weak dose-response relationship."	( Intraocular pressure-reducing effect of PhXA41 in patients with increased eye pressure. A one-month study. Airaksinen, J; Alm, A; Mandahl, A; Marsk, A; Resul, B; Stjernschantz, J; Törnquist, P; Tuulonen, A; Villumsen, J, 1993)	0.29
" The IOP-lowering effect of latanoprost lasts for 20 to 24 hours after a single dose, which allows a single daily dosage regimen."	( Latanoprost. A review of its pharmacological properties, clinical efficacy and tolerability in the management of primary open-angle glaucoma and ocular hypertension. Patel, SS; Spencer, CM, 1996)	0.29
" New anti-glaucoma drugs, latanoprost and nipradilol, have been shown to effect a reduction in IOP equal to that achieved with the equivalent dosage of timolol, with no adverse systemic side effects."	( [Current topics in glaucoma]. Masuda, K, 1996)	0.29
"005%, once-a-day dosing of latanoprost is highly effective in significantly reducing intraocular pressure, causing only minimal, clinically acceptable short-term ocular side effects."	( Clinical dose-regimen studies with latanoprost, a new ocular hypotensive PGF2 alpha analogue. Diestelhorst, M; Krieglstein, GK; Lusky, M; Nagasubramanian, S, 1997)	0.3
" Outflow facility was measured in six normal monkeys 3 hours prior to dosing and 1 hour after unilateral dosing with either drug."	( A comparative study of latanoprost (Xalatan) and isopropyl unoprostone (Rescula) in normal and glaucomatous monkey eyes. Kitazawa, Y; Podos, SM; Serle, JB; Wang, RF, )	0.13
"It is known that twice daily dosing of latanoprost is less effective in reducing intraocular pressure (IOP) than once daily applications."	( Latanoprost twice daily is less effective than once daily: indication of receptor subsensitivity? Alm, A; Lindén, C, 1998)	0.3
"The results of the present study are compatible with development of subsensitivity, at the level of the FP-receptor or its associated intracellular signaling pathways, with twice- but not with once-daily dosing of latanoprost."	( Latanoprost twice daily is less effective than once daily: indication of receptor subsensitivity? Alm, A; Lindén, C, 1998)	0.3
"To study any interaction between pilocarpine and latanoprost when administered together, and to determine the optimal timing of dosage to maximize reduction of intraocular pressure (IOP)."	( Interaction of pilocarpine with latanoprost in patients with glaucoma and ocular hypertension. Crosson, CE; Hebert, RL; Kent, AR; Thomas, TJ; Vroman, DT, 1999)	0.3
" There were no significant differences between dosage schedules in the magnitude of the additional reduction in IOP."	( Interaction of pilocarpine with latanoprost in patients with glaucoma and ocular hypertension. Crosson, CE; Hebert, RL; Kent, AR; Thomas, TJ; Vroman, DT, 1999)	0.3
"To compare the 24-hour diurnal ocular hypotensive efficacy of two dosing regimens of latanoprost, once daily (8 AM or 10 PM), vs timolol maleate, twice daily."	( Comparison of 24-hour intraocular pressure reduction with two dosing regimens of latanoprost and timolol maleate in patients with primary open-angle glaucoma. Gandi, S; Hudgins, AC; Konstas, AG; Maltezos, AC; Stewart, WC, 1999)	0.3
"005% given at 8 AM or 10 PM for 1 month and then changed to the other dosing regimen for 1 month."	( Comparison of 24-hour intraocular pressure reduction with two dosing regimens of latanoprost and timolol maleate in patients with primary open-angle glaucoma. Gandi, S; Hudgins, AC; Konstas, AG; Maltezos, AC; Stewart, WC, 1999)	0.3
" When dosed according to labeling, latanoprost had the lowest cost of therapy at $0."	( Daily cost of newer glaucoma agents. Hudgins, AC; Pruitt, CA; Sine, C; Stewart, WC, 1999)	0.3
" The peak level 2 hours after dosing for timolol hemihydate was 16."	( Efficacy and safety of timolol solution once daily vs timolol gel added to latanoprost. Day, DG; Dubiner, HB; Holmes, KT; Sharpe, ED; Stewart, JA; Stewart, WC, 1999)	0.3
" Recommended dosing is once daily at bedtime."	( Prostaglandin analogs in the treatment of glaucoma. Camras, CB; Hejkal, TW, 1999)	0.3
" The once daily dosing promotes compliance."	( Therapeutic potential of prostaglandin analogues in glaucoma. Lindén, C, 2001)	0.31
" This prospective study included 59 NTG and 20 POAG patients treated with the following four dosing regimens of latanoprost: patients on no previous medication received latanoprost as initial therapy (Group 1, n=31), patients on beta-blocker therapy received latanoprost as adjunctive therapy (Group II, n=9), patients on unoprostone monotherapy were switched to latanoprost monotherapy (Group III, n=14), and patients previously on dual therapy with isopropyl unoprostone and beta-blocker were switched to a combined treatment of latanoprost and beta-blocker (Group IV, n=25)."	( Intraocular pressure-lowering efficacy of latanoprost in patients with normal-tension glaucoma or primary open-angle glaucoma. Kitazawa, Y; Murase, H; Tamada, Y; Taniguchi, T; Yamamoto, T, 2001)	0.31
"This study suggests latanoprost dosed daily in the evening statistically reduces intraocular pressure more during daytime and evening hours than brimonidine dosed twice daily."	( The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension. Day, DG; Latham, KE; Schuhr, J; Stewart, JA; Stewart, WC, 2001)	0.31
"Although IOP was reduced with every 24-hour dosing of latanoprost, the frequency of prostaglandin-induced adverse events was high."	( Effects of topical administration of 0.005% latanoprost solution on eyes of clinically normal horses. Diehl, KA; Hoshaw-Woodard, S; Kobayashi, I; Schmall, LM; Vitucci, MP; Willis, AM, 2001)	0.31
" The reduction in IOP was maintained throughout the 24-hour dosage interval."	( Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension. Easthope, SE; Perry, CM, 2002)	0.31
"1 mm Hg) dosed latanoprost/timolol maleate compared with timolol maleate given twice daily (21."	( A comparison of once-daily morning vs evening dosing of concomitant latanoprost/timolol. Konstas, AG; Lallos, NA; Leech, JN; Nakos, E; Stewart, WC; Tersis, I, 2002)	0.31
"Rates of medication discontinuation reflect factors including effectiveness, tolerability, cost, and dosing frequency."	( Discontinuation rates of topical glaucoma medications in a managed care population. Cho, J; Mullins, CD; Shaya, FT; Wong, W, 2002)	0.31
"3%) mainly because of its once daily dosing (P < 0001)."	( The efficacy and safety of the timolol/dorzolamide fixed combination vs latanoprost in exfoliation glaucoma. Konstas, AG; Kozobolis, VP; Leech, J; Stewart, WC; Tersis, I, 2003)	0.32
"We evaluated conjunctival hyperemia by a standard photographic measure at the slit lamp and by anterior segment photographs in healthy subjects after dosing for 5 days with latanoprost, bimatoprost, or travoprost."	( Conjunctival hyperemia in healthy subjects after short-term dosing with latanoprost, bimatoprost, and travoprost. Jackson, AL; Kolker, AE; Leech, J; Stewart, JA; Stewart, WC, 2003)	0.32
"005% lasts for up to 24 hours after a single topical dose, which allows for a once-daily dosage regimen."	( Latanoprost : an update of its use in glaucoma and ocular hypertension. Culy, CR; Ibbotson, T; McGavin, JK; Perry, CM, 2003)	0.32
" This may occur, despite a significant reduction in IOP, because the reached IOP is not sufficient enough to avoid further deterioration because the patient's work or social activities do not allow a correct daily dosage of the compound (bad compliance); or as a result of treatment suspension, because of the development of systemic and/or local side effects."	( Assessing the cost-effectiveness of switching from a beta-blocker to latanoprost in the treatment of ocular hypertension. Costagliola, C; Parmeggiani, F; Sebastiani, A, 2003)	0.32
"A single centered, active-controlled, three-period crossover comparison that evaluated conjunctival and corneal punctate staining, by grade and individual stains, in healthy subjects after dosing for five days in one eye with latanoprost, bimatoprost, or travoprost."	( Corneal punctate staining with latanoprost, bimatoprost, and travoprost in healthy subjects. Jackson, AL; Jenkins, JN; Stewart, JA; Stewart, WC, 2003)	0.32
"33) or at 1 hour after dosing (latanoprost 23."	( Corneal punctate staining with latanoprost, bimatoprost, and travoprost in healthy subjects. Jackson, AL; Jenkins, JN; Stewart, JA; Stewart, WC, 2003)	0.32
" These agents are typically dosed once daily."	( Comparison of the diurnal ocular hypotensive efficacy of travoprost and latanoprost over a 44-hour period in patients with elevated intraocular pressure. Andrew, RM; Bergamini, MV; Darell Turner, F; Dubiner, HB; Landry, T; Przydryga, J; Robertson, S; Silver, LH; Sircy, MD; Weiner, A, 2004)	0.32
" Due to the unique mechanism of action of latanoprost, once-daily dosing of one drop of FC latanoprost/timolol results in additional IOP reduction compared with either drug administered separately."	( An evaluation of the fixed-combination of latanoprost and timolol for use in open-angle glaucoma and ocular hypertension. Feldman, RM, 2004)	0.32
"Fixed combination latanoprost/timolol administered once daily is both more effective and better tolerated than twice daily dosing with UFC brimonidine/timolol."	( A comparison of the fixed combination of latanoprost and timolol with the unfixed combination of brimonidine and timolol in patients with elevated intraocular pressure. A six month, evaluator masked, multicentre study in Europe. Cunliffe, I; García-Sánchez, J; Landry, J; Pajic, B; Rouland, JF; Spiegel, D; Traverso, C, 2004)	0.32
" The following 5 different dosing protocols were studied: latanoprost with bimatoprost added, bimatoprost with latanoprost added, latanoprost with travoprost added, travoprost with latanoprost added, and latanoprost with a second dose of latanoprost added."	( Additivity of bimatoprost or travoprost to latanoprost in glaucomatous monkey eyes. Gagliuso, DJ; Mittag, TW; Podos, SM; Wang, RF, 2004)	0.32
"005% dosed once in the evening."	( A comparison of the effects of dorzolamide/timolol fixed combination versus latanoprost on intraocular pressure and pulsatile ocular blood flow in primary open-angle glaucoma patients. Harris, A; Janulevicienë, I; Kagemann, L; McCranor, L; Siesky, B, 2004)	0.32
"In previous analyses of primary efficacy data from two randomized clinical trials, standard dosing regimens of the dorzolamide/timolol fixed combination (COSOPT) and latanoprost (XALATAN) were shown to have equivalent efficacy with regard to reduction in mean daytime diurnal intraocular pressure (IOP)."	( Efficacy of the dorzolamide/timolol fixed combination versus latanoprost in the treatment of ocular hypertension or glaucoma: combined analysis of pooled data from two large randomized observer and patient-masked studies. Adamsons, IA; Fechtner, RD; Lines, CR; McCarroll, KA, 2005)	0.33
"A prospective, observer-masked, crossover, active-controlled, randomized comparison in which after a 6-week medicine-free period, patients were randomized to either latanoprost-timolol-fixed combination therapy or latanoprost therapy, both dosed once each evening, alone for 8 weeks."	( Twenty-four-hour control with latanoprost-timolol-fixed combination therapy vs latanoprost therapy. Boboridis, K; Jenkins, JN; Kallinderis, K; Konstas, AG; Stewart, WC; Tzetzi, D, 2005)	0.33
"005% (Xalatan) dosed once daily in patients with primary open-angle glaucoma or ocular hypertension."	( Circadian IOP-lowering efficacy of travoprost 0.004% ophthalmic solution compared to latanoprost 0.005%. Castillo, A; Fernández-Vidal, A; García-Feijoo, J; García-Sánchez, J; Martínez-de-la-Casa, JM; Méndez, C, 2006)	0.33
"After a medicine-free period, qualified patients were randomized to either placebo dosed in the morning with a latanoprost-timolol fixed combination dosed in the evening or timolol alone dosed twice daily for 8 weeks."	( 24-Hour control with a latanoprost-timolol fixed combination vs timolol alone. Economou, AI; Jenkins, JN; Kaltsos, K; Konstas, AG; Lake, S; Stewart, WC, 2006)	0.33
" A second group of animals was exposed to the medications through a dosing regimen of 1 drop/min (lpar3 drops total) (n=4/group)."	( Assessment of corneal epithelial integrity after acute exposure to ocular hypotensive agents preserved with and without benzalkonium chloride. Cavanagh, HD; Lakshman, N; Petroll, WM; Whitson, JT, )	0.13
"5% ophthalmic solution (Lat/Tim), dosed once daily in the morning, in patients with open-angle glaucoma (OAG) or ocular hypertension (OH)."	( A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. Andrew, R; Danesh-Meyer, H; Kozobolis, V; Melamed, S; Topouzis, F; Wells, AP; Wells, D; Wieland, H, )	0.13
"Both morning and evening dosing of LTFC were effective in lowering diurnal IOP in patients with POAG."	( Comparison of intraocular pressure lowering effect of once daily morning vs evening dosing of latanoprost/timolol maleate combination. Aşik, S; Can, I; Gurdal, C; Kürkçüoğlu, P; Takmaz, T, )	0.13
"Once-daily dosing of travoprost with sofZia produced significantly fewer corneal changes and less conjunctival inflammation than latanoprost preserved with BAK."	( Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears. Kahook, MY; Noecker, RJ, 2008)	0.35
" dosing of dorzolamide."	( Comparison of twice-daily and three-times-daily dosing of dorzolamide in ocular hypertension and primary open-angle glaucoma patients treated with latanoprost. Evans, D; Fung, KH; Lupinacci, AP; Netland, PA; Zhao, Y, 2008)	0.35
"00) dosing of dorzolamide, treated in both eyes for 4 weeks, washed out for 3 weeks, then switched to the opposite dosing frequency for 4 weeks."	( Comparison of twice-daily and three-times-daily dosing of dorzolamide in ocular hypertension and primary open-angle glaucoma patients treated with latanoprost. Evans, D; Fung, KH; Lupinacci, AP; Netland, PA; Zhao, Y, 2008)	0.35
" dosing of dorzolamide did not significantly affect a change in IOP except at one afternoon time point."	( Comparison of twice-daily and three-times-daily dosing of dorzolamide in ocular hypertension and primary open-angle glaucoma patients treated with latanoprost. Evans, D; Fung, KH; Lupinacci, AP; Netland, PA; Zhao, Y, 2008)	0.35
"To compare the 12-hour efficacy and safety of dorzolamide/timolol fixed combination (DTFC) dosed twice daily versus latanoprost dosed every evening following a timolol run-in in primary open-angle glaucoma patients."	( Comparison of daytime efficacy and safety of dorzolamide/timolol maleate fixed combination versus latanoprost. Ahmad, A; Mulaney, J; Sonty, S; Stewart, JA; Stewart, WC, )	0.13
" Patients with an IOP of 22-29 mmHg inclusive at 8 AMwere randomized to either bimatoprost dosed each evening or DTFC twice-daily."	( A comparison of dorzolamide/timolol-fixed combination versus bimatoprost in patients with open-angle glaucoma who are poorly controlled on latanoprost. Nelson, LA; Sharpe, ED; Stewart, JA; Stewart, WC; Williams, RD, 2008)	0.35
" Patient dosing preference (a."	( Comparison of morning versus evening dosing and 24-h post-dose efficacy of travoprost compared with latanoprost in patients with open-angle glaucoma . Battista, RA; Haidich, AB; Konstas, AG; Yan, DB, 2008)	0.35
"The mean IOP in the first period when all patients were dosed in the evening was assessed 12 h after dosing at 09:00 and it was similar in the two treatment groups (mean ± standard deviation: 17."	( Comparison of morning versus evening dosing and 24-h post-dose efficacy of travoprost compared with latanoprost in patients with open-angle glaucoma . Battista, RA; Haidich, AB; Konstas, AG; Yan, DB, 2008)	0.35
"Patients with primary open-angle glaucoma or ocular hypertension with normal blood pressure were randomized to LTFC, dosed each evening, or timolol dosed twice daily in a cross-over design for 8 weeks and the opposite medicine for 8 weeks."	( 24-hour intraocular pressure and blood pressure levels with latanoprost/timolol fixed combination versus timolol. Konstas, AG; Kozobolis, VP; Lasaridis, AN; Mikropoulos, D; Nelson, LA; Pikilidou, MI; Sarafidis, PA; Stewart, WC; Tsironi, S, 2009)	0.35
" This model-based meta-analysis validates previous findings that evening dosing is superior to morning dosing and predicts the optimal time for dosing, based on the quantitative assessment of baseline and latanoprost-treated 24-h circadian intraocular pressure (IOP) curves."	( A model-based meta-analysis of the effect of latanoprost chronotherapy on the circadian intraocular pressure of patients with glaucoma or ocular hypertension. Luu, KT; Nickens, DJ; Raber, SR; Vicini, P, 2010)	0.36
"After up to a 6-week medicine-free period, XFG patients were randomized to either TTFC or LTFC for 3 months, dosed each evening, and then changed to the opposite treatment for another 3 months."	( 24-h Intraocular pressure control with evening-dosed travoprost/timolol, compared with latanoprost/timolol, fixed combinations in exfoliative glaucoma. Dimopoulos, AT; Embeslidis, TA; Haidich, AB; Konstas, AG; Mikropoulos, DG; Papanastasiou, A; Stewart, WC, 2010)	0.36
"2%) and desire to simplify treatment with once-daily dosing (29."	( Long-term effect of latanoprost/timolol fixed combination in patients with glaucoma or ocular hypertension: a prospective, observational, noninterventional study. Guzy, C; Heckmann, B; Miller, PJ; Schwenn, O, 2010)	0.36
" The potential benefit to the human ocular surface with oncedaily dosing needs to be evaluated clinically."	( Polyquad-preserved travoprost/timolol, benzalkonium chloride (BAK)-preserved travoprost/timolol, and latanoprost/timolol in fixed combinations: a rabbit ocular surface study. Baudouin, C; Brignole-Baudouin, F; Liang, H; Pauly, A; Riancho, L, 2011)	0.37
"This 8-week, randomized, open-label, parallel-group, noninferiority study compared once-daily evening dosing of LTFC with the unfixed combination of latanoprost, one drop in the evening, and timolol, one drop in the morning (LTuFC)."	( Comparative efficacy and safety of the fixed versus unfixed combination of latanoprost and timolol in Chinese patients with open-angle glaucoma or ocular hypertension. Ge, J; Li, XX; Li, YM; Sheng, YH; Sun, NX; Sun, XH; Yao, K; Zhao, JL; Zhong, Z, 2011)	0.37
"UBM revealed cyclodialysis in the patient's affected eye after a single dosage of bimatoprost."	( A case hypersensitive to bimatoprost and dexamethasone. Li, X; Liu, G; Liu, X; Wang, Y; Xiang, H; Yu, W, 2011)	0.37
" Each participant underwent aqueous humor dynamics measurements at baseline and at 2 weeks of dosing in random order with latanoprost in the evening and placebo in the morning, timolol maleate twice daily, and dorzolamide hydrochloride twice daily."	( Diurnal and nocturnal variations in aqueous humor dynamics of patients with ocular hypertension undergoing medical therapy. Fan, S; Gangahar, C; Gulati, V; Maslonka, MA; Toris, CB; Zhao, M, 2012)	0.38
"005% (n = 75, dosed in the evening, with vehicle control in the morning to maintain masking) for 12 weeks."	( Fixed-combination brimonidine-timolol versus latanoprost in glaucoma and ocular hypertension: a 12-week, randomized, comparison study. Cottingham, AJ; Hollander, DA; Katz, LJ; Rauchman, SH; Schiffman, RM; Simmons, ST; Williams, JM, 2012)	0.38
" After 1 month, eyes were crossed over to the opposite dosing regimen for another month."	( Intraocular pressure-lowering effect of 0.005% latanoprost with two different dosing regimens. Naghibi, A; Nilforushan, N; Nouri-Mahdavi, K; Shokrollahi, S; Soltan Sanjari, M, 2012)	0.38
" Since the lack of compliance with topical ocular dosing may compromise efficacy, alternate methods of delivery are being sought."	( Safety assessment of subconjunctivally implanted devices containing latanoprost in Dutch-belted rabbits. Evans, M; Guo, H; Jessen, BA; Kaur, H; Leedle, R; Miller, P; Shiue, MH, )	0.13
" Multiday dosing (daily for 3 days) of latanoprost also was evaluated."	( Prostaglandin analog effects on cerebrospinal fluid reabsorption via nasal mucosa. Pedler, MG; Petrash, JM; Subramanian, PS, 2021)	0.62
" Razuprotafib QD dosing did not demonstrate additional IOP lowering compared to latanoprost alone."	( Tie2 Activation via VE-PTP Inhibition With Razuprotafib as an Adjunct to Latanoprost in Patients With Open Angle Glaucoma or Ocular Hypertension. Brigell, M; Buch, A; Peters, KG; Withers, B, 2022)	0.72
"The purpose of this study was to compare varying concentrations of NCX 470 (a nitric oxide-donating bimatoprost) to latanoprost in a dose-response safety and efficacy trial."	( A Randomized, Controlled Comparison of NCX 470 (0.021%, 0.042%, and 0.065%) and Latanoprost 0.005% in Patients With Open-angle Glaucoma or Ocular Hypertension: The Dolomites Study. Boyer, JL; Duquesroix, B; Fechtner, RD; Kothe, AC; Lopez, K; Navratil, T; Usner, DW; Walters, TR, 2022)	0.72
" This would be achieved with a once daily dosing regimen to preserve glaucoma patients' vision, ocular surface, and quality-of-life and wellness."	( Use of a Cationic Emulsion of Latanoprost to Treat Glaucoma Patients with Ocular Surface Disease: A Preclinical Review. Baudouin, C; Daull, P; Garrigue, JS; Liang, H, 2023)	0.91

Role	Description
antiglaucoma drug	Any drug which can be used to prevent or alleviate glaucoma, a disease in which the optic nerve is damaged, resulting in progressive, irreversible loss of vision. It is often, though not always, associated with increased pressure of the fluid in the eye.
antihypertensive agent	Any drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism.
EC 4.2.1.1 (carbonic anhydrase) inhibitor	An EC 4.2.1.* (hydro-lyases) inhibitor that interferes with the action of carbonic anhydrase (EC 4.2.1.1). Such compounds reduce the secretion of H(+) ions by the proximal kidney tubule.
prodrug	A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
prostaglandins Falpha
triol	A chemical compound containing three hydroxy groups.
isopropyl ester	Any carboxylic ester resulting from the formal condensation of a carboxylic acid with the hydroxy group of propan-2-ol.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, Beta-lactamase	Escherichia coli K-12	Potency	11.2202	0.0447	17.8581	100.0000	AID485341
Chain A, 2-oxoglutarate Oxygenase	Homo sapiens (human)	Potency	25.1189	0.1778	14.3909	39.8107	AID2147
Microtubule-associated protein tau	Homo sapiens (human)	Potency	5.0119	0.1800	13.5574	39.8107	AID1460
beta-2 adrenergic receptor	Homo sapiens (human)	Potency	35.4813	0.0058	6.0263	32.6427	AID492947
mitogen-activated protein kinase 1	Homo sapiens (human)	Potency	12.5893	0.0398	16.7842	39.8107	AID1454
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
ATP-binding cassette sub-family C member 3	Homo sapiens (human)	IC50 (µMol)	133.0000	0.6315	4.4531	9.3000	AID1473740
Multidrug resistance-associated protein 4	Homo sapiens (human)	IC50 (µMol)	133.0000	0.2000	5.6774	10.0000	AID1473741
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	12.9000	0.1100	7.1903	10.0000	AID1473738
Canalicular multispecific organic anion transporter 1	Homo sapiens (human)	IC50 (µMol)	133.0000	2.4100	6.3433	10.0000	AID1473739
Solute carrier organic anion transporter family member 2A1	Homo sapiens (human)	Ki	10.0000	0.0230	0.0700	0.1490	AID679659
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
xenobiotic metabolic process	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
bile acid and bile salt transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
leukotriene transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
monoatomic anion transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transport across blood-brain barrier	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
prostaglandin secretion	Multidrug resistance-associated protein 4	Homo sapiens (human)
cilium assembly	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet degranulation	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic metabolic process	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
bile acid and bile salt transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
cAMP transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
leukotriene transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
monoatomic anion transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
export across plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
transport across blood-brain barrier	Multidrug resistance-associated protein 4	Homo sapiens (human)
guanine nucleotide transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
negative regulation of gene expression	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bile acid and bile salt transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
heme catabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic export from cell	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transepithelial transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
leukotriene transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
monoatomic anion transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
lipid transport	Solute carrier organic anion transporter family member 2A1	Homo sapiens (human)
sodium-independent organic anion transport	Solute carrier organic anion transporter family member 2A1	Homo sapiens (human)
transmembrane transport	Solute carrier organic anion transporter family member 2A1	Homo sapiens (human)
prostaglandin transport	Solute carrier organic anion transporter family member 2A1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
ATP binding	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type bile acid transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATP hydrolysis activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
icosanoid transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
guanine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
purine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type bile acid transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
efflux transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP hydrolysis activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
protein binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP hydrolysis activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
lipid transporter activity	Solute carrier organic anion transporter family member 2A1	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Solute carrier organic anion transporter family member 2A1	Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activity	Solute carrier organic anion transporter family member 2A1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basal plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basolateral plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
nucleolus	Multidrug resistance-associated protein 4	Homo sapiens (human)
Golgi apparatus	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet dense granule membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
external side of apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cell surface	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
intercellular canaliculus	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
lysosome	Solute carrier organic anion transporter family member 2A1	Homo sapiens (human)
plasma membrane	Solute carrier organic anion transporter family member 2A1	Homo sapiens (human)
basal plasma membrane	Solute carrier organic anion transporter family member 2A1	Homo sapiens (human)
membrane	Solute carrier organic anion transporter family member 2A1	Homo sapiens (human)
basolateral plasma membrane	Solute carrier organic anion transporter family member 2A1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID588215	FDA HLAED, alkaline phosphatase increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID126796	Maximum reduction of the intraocular pressure in normotensive monkeys after topical administration of 3 ug of the compound	1993	Journal of medicinal chemistry, Jan-22, Volume: 36, Issue:2	Phenyl-substituted prostaglandins: potent and selective antiglaucoma agents.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588214	FDA HLAED, liver enzyme composite activity	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588216	FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1473741	Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID418262	Increase in glutathione levels in aqueous humor of carbomer-induced glaucomatous pigmented rabbit at 0.005%, topical administration continuously for 5 days by fluorimetry	2009	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6	New prostaglandin derivative for glaucoma treatment.
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588219	FDA HLAED, gamma-glutamyl transferase (GGT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1473784	Drug concentration at steady state in human at 1.5 ug administered as 1 drop intraocularly QD after 24 hrs	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1473739	Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID588218	FDA HLAED, lactate dehydrogenase (LDH) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1473738	Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID418263	Increase in cGMP levels in aqueous humor of carbomer-induced glaucomatous pigmented rabbit at 0.005%, topical administration continuously for 5 days by radioimmunoassay	2009	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6	New prostaglandin derivative for glaucoma treatment.
AID1473740	Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID588217	FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID417991	Effect on intraocular pressure in carbomer-induced glaucoma in New Zealand albino rabbit assessed as AUC at 0.005%, topical administration measured after 4 hrs	2009	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6	New prostaglandin derivative for glaucoma treatment.
AID48546	Maximum irritation of cat eyes after topical administration of 3 ug of the compound	1993	Journal of medicinal chemistry, Jan-22, Volume: 36, Issue:2	Phenyl-substituted prostaglandins: potent and selective antiglaucoma agents.
AID418259	Increase in glutathione levels in aqueous humor of normotensive pigmented rabbit at 0.005%, topical administration	2009	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6	New prostaglandin derivative for glaucoma treatment.
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID417989	Effect on intraocular pressure in carbomer-induced glaucoma in pigmented rabbit assessed as AUC at 0.005%, topical administration continuously for 5 days measured after 4 hrs by fluorimetry	2009	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6	New prostaglandin derivative for glaucoma treatment.
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID485979	Inhibition of CETP in rabbit serum at 10 uM after 1 hr by fluorescent cholesteryl esters transfer assay	2010	European journal of medicinal chemistry, Apr, Volume: 45, Issue:4	Discovery of new cholesteryl ester transfer protein inhibitors via ligand-based pharmacophore modeling and QSAR analysis followed by synthetic exploration.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1473783	AUC in human at 1.5 ug administered as 1 drop intraocularly QD after 24 hrs	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID417992	Effect on intraocular pressure in carbomer-induced glaucoma in pigmented rabbit assessed as AUC at 0.005%, topical administration continuously for 5 days	2009	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6	New prostaglandin derivative for glaucoma treatment.
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1473785	Ratio of drug concentration at steady state in human at 1.5 ug administered as 1 drop intraocularly QD after 24 hrs to IC50 for human BSEP overexpressed in Sf9 insect cells	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID679659	TP_TRANSPORTER: inhibition of PGE1 uptake (PGE1: 0.0004 uM) in PGT-expressing HeLa cells	2002	Experimental eye research, Jan, Volume: 74, Issue:1	Comparison between isopropyl unoprostone and latanoprost by prostaglandin E(2)induction, affinity to prostaglandin transporter, and intraocular metabolism.
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1346394	Human FP receptor (Prostanoid receptors)	2000	Biochimica et biophysica acta, Jan-17, Volume: 1483, Issue:2	The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	174 (12.07)	18.2507
2000's	728 (50.49)	29.6817
2010's	423 (29.33)	24.3611
2020's	117 (8.11)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	527 (33.19%)	5.53%
Reviews	155 (9.76%)	6.00%
Case Studies	169 (10.64%)	4.05%
Observational	15 (0.94%)	0.25%
Other	722 (45.47%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (211)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Phase 1, Open-label, Dose Escalation Study to Evaluate the Safety and Tolerability of Latanoprost Sustained Release (SR) Insert in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) [NCT01180062]	Phase 1	12 participants (Actual)	Interventional	2011-01-31	Terminated(stopped due to Study terminated early due to manufacturer not replenishing study site supply of inserts, despite repeated requests for more inserts.)
Topical Application of Latanoprost in Diabetic Retinopathy [NCT01225653]	Phase 4	27 participants (Actual)	Interventional	2010-11-30	Completed
Effect of Alphagan and Xalatan Eye Drops on Corneal Temperature [NCT01201551]		40 participants (Actual)	Interventional	2011-06-30	Completed
A Phase I, Multi-Center, Randomized, Adaptive, Investigator/Patient Masked, Multiple-Ascending Dose, Placebo and Active Comparator-Controlled Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7058584 Follo [NCT03293992]	Phase 1	27 participants (Actual)	Interventional	2017-10-10	Completed
Effects of Latanoprost, Bimatoprost and Travoprost in Patients With Latanoprost-resistant Glaucoma [NCT01361841]		141 participants (Anticipated)	Interventional	2009-01-31	Recruiting
Effectiveness of Microneedling and Topical Latanoprost in Treatment of Acrofacial Vitiligo [NCT03611348]	Phase 2/Phase 3	70 participants (Anticipated)	Interventional	2018-09-01	Not yet recruiting
[NCT02047630]	Phase 4	60 participants (Anticipated)	Interventional	2014-01-31	Terminated(stopped due to Problem with IP supply)
Multi Center, Randomized, Double-blind, Active Controlled, Parallel Design, Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-351 in Primary Open Angle Glaucoma or Ocular Hypertension Patients [NCT03762369]	Phase 3	384 participants (Anticipated)	Interventional	2018-12-07	Not yet recruiting
A Prospective, Double-masked, Randomized, Multicenter, Active-controlled, Parallel-group, 6-month Study Assessing the Safety and Ocular Hypotensive Efficacy of PG324 Ophthalmic Solution Compared to GANFORT® (Bimatoprost 0.03% / Timolol 0.5%) Ophthalmic So [NCT03284853]	Phase 3	436 participants (Actual)	Interventional	2017-09-05	Completed
Phase II, Randomized, Double-masked, Active-controlled Study of Fixed-Dose Combinations of Trabodenoson and Latanoprost in Subjects With Ocular Hypertension or Primary Open-Angle Glaucoma [NCT02829996]	Phase 2	201 participants (Actual)	Interventional	2016-08-19	Completed
A Phase 1, Open-Label Study of Latanoprost Acid Plasma Concentrations in Pediatric and Adult Glaucoma Patients Treated With Latanoprost 0.005%. [NCT00638742]	Phase 1	47 participants (Actual)	Interventional	2008-05-31	Completed
Choroidal Thickness and Its Correlations With Ocular Parameters in Cases With Primary Open-angle Glaucoma [NCT03966560]	Phase 4	96 participants (Actual)	Interventional	2014-01-31	Completed
Comparison of the Effects of Latanoprost(0.005%) and Brinzolamide(1.0%) on Intraocular Pressure in Primary Open-angle Glaucoma and Ocular Hypertension [NCT01084902]		130 participants (Actual)	Interventional	2010-02-28	Active, not recruiting
Examination of Ocular Surface Effects With Administration of TRAVATAN Z® and Xalatan® [NCT00708422]	Phase 4	231 participants (Actual)	Interventional	2008-07-31	Completed
Safety, Tolerability and Preliminary Efficacy of Unilateral Latanoprost-loaded Punctual Plug in Patients With Open Angle Early Visual Field Defects Glaucoma or Ocular Hypertension in Comparison to Xalatan © Eye Drops in the Second Eye [NCT03318146]		40 participants (Anticipated)	Interventional	2018-06-01	Not yet recruiting
An Evaluation of the Usability and Patient Tolerability for Microtherapeutic Dosing of Commercially Available Ocular Medication Via the Eyenovia Microdose Delivery System (MiDD) [NCT03480906]		30 participants (Actual)	Interventional	2018-03-12	Completed
A Phase 2, Double-masked, Randomized, Active-controlled, Crossover Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 or Timolol Added to Patients With Elevated Intraocular Pressure Currently Using Latanoprost [NCT01302249]	Phase 2	66 participants (Actual)	Interventional	2011-02-28	Completed
[NCT00761709]	Phase 2	104 participants (Actual)	Interventional	2009-07-31	Completed
A Randomised Control Study to Investigate if the Continuation of Prostaglandin Analogue Treatments in the Post-operative Phase of Glaucoma Patients Undergoing Cataract Surgery Increases the Incidence of Cystoid Macular Oedema. [NCT03292796]	Phase 2	56 participants (Actual)	Interventional	2016-12-07	Completed
Comparison Between the Effect of Latanoprost 0.005%, Travoprost 0.004% and Tafluprost 0.0015% on Diurnal Intraocular Pressure Fluctuation in Patients Having Primary Open-angle Glaucoma [NCT04461249]		60 participants (Actual)	Observational	2019-06-01	Completed
African Glaucoma Laser Trial [NCT03648229]	Phase 4	0 participants (Actual)	Interventional	2019-09-01	Withdrawn(stopped due to Funding unavailable)
Multi Center, Randomized, Open-label, Active Controlled, Phase 2 Trial, Proof Of Concept Study to Evaluate the Efficacy and Safety of CKD-351 in Primary Open Angle Glaucoma or Ocular Hypertension Patients [NCT04448223]	Phase 2	100 participants (Anticipated)	Interventional	2020-06-11	Recruiting
An Investigator-Masked, Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics, and Efficacy of OPA-6566 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension [NCT01410188]	Phase 1/Phase 2	160 participants (Actual)	Interventional	2011-09-30	Completed
An Open-Label, Phase 2 Study of the Latanoprost Punctal Plug Delivery System (L-PPDS) With Adjunctive Xalatan® Eye Drops in Subjects With Ocular Hypertension (OH) or Open-Angle Glaucoma (OAG) [NCT01037036]	Phase 2	15 participants (Actual)	Interventional	2009-12-31	Completed
A Phase II, Randomized, Masked, Parallel-Group Study of Safety and Preliminary Efficacy of the Punctum Plug Delivery System in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension [NCT00650702]	Phase 2	36 participants (Actual)	Interventional	2008-03-31	Completed
Special Investigation Of Long Term Use Of Xalacom(Regulatory Post Marketing Commitment Plan) [NCT01191008]		661 participants (Actual)	Observational	2010-10-31	Completed
[NCT02179008]	Phase 2	184 participants (Actual)	Interventional	2014-06-30	Completed
Evaluation of Glaucoma or Ocular Hypertension Patients With Pre-existing Ocular Surface Disease Switched From a Preserved Prostaglandin Analog - Timolol Fixed Combination to a Preservative - Free Latanoprost - Timolol Fixed Combination [NCT04891588]		50 participants (Anticipated)	Interventional	2021-03-08	Recruiting
A Phase 2 Study Evaluating Safety and Efficacy of the Latanoprost Punctal Plug Delivery System (L PPDS)in Subjects With Ocular Hypertension (OH) or Open Angle Glaucoma (OAG) [NCT01229982]	Phase 2	121 participants (Actual)	Interventional	2010-10-31	Completed
Latanoprost Plus NB-UVB Versus Each Alone in Non-segmental Vitiligo: Clinical and Laboratory Evaluation [NCT04811326]	Phase 4	150 participants (Anticipated)	Interventional	2021-01-13	Active, not recruiting
Comparison of Safety and Efficacy of Al-37807 Ophthalmic Suspension vs. Timolol Gel Forming Solution and Vehicle, All Dosed Concomitantly With Xalatan in Patients With Open-Angle Glaucoma or Ocular Hypertension [NCT00620256]	Phase 2	129 participants (Actual)	Interventional	2007-11-30	Completed
A Phase 1/2 Multicenter, Randomized, Controlled Dose-Finding Study to Evaluate the Safety and Ocular Hypotensive Efficacy of 3 Dose Levels of the VS101 Subconjunctival Latanoprost Insert for 3 Months in Subjects With Open-Angle Glaucoma or Ocular Hyperten [NCT02129673]	Phase 1/Phase 2	77 participants (Actual)	Interventional	2014-05-31	Completed
[NCT01318252]	Phase 2	64 participants (Actual)	Interventional	2011-06-30	Completed
A Phase 2, Randomized Study Evaluating the Safety and Efficacy of Catioprost® (Unpreserved Latanoprost 0.005% Emulsion) Compared to Travatan Z® in Subjects With Glaucoma or Ocular Hypertension and Ocular Surface Disease [NCT01254370]	Phase 2	105 participants (Actual)	Interventional	2010-11-30	Completed
[NCT00892762]	Phase 3	434 participants (Actual)	Interventional	2009-06-30	Completed
An Open-Label, Phase 2 Study of Punctal Placement of the Latanoprost Punctal Plug System (L-PPDS) in Subjects With Ocular Hypertension (OH) or Open-Angle Glaucoma (OAG) [NCT00821002]	Phase 2	32 participants (Actual)	Interventional	2009-01-31	Completed
An Open-Label, Phase 2 Study of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension (OH) or Open Angle Glaucoma (OAG) [NCT00820300]	Phase 2	113 participants (Actual)	Interventional	2009-01-31	Completed
Circadian Rhythms of Aqueous Humor Dynamics in Humans [NCT00572936]	Phase 2	30 participants (Actual)	Interventional	2006-03-13	Completed
Stop Retinal Ganglion Cell Dysfunction Study [NCT02390284]	Phase 3	500 participants (Anticipated)	Interventional	2015-09-30	Active, not recruiting
Comparative Evaluation of Intraocular Pressure During the 24 Hour in Patients Affected by Primary Open-angle Glaucoma and Ocular Hypertension: Latanoprost 0.005% Versus Tafluprost 0.0015% Ophthalmic Solutions [NCT01162603]	Phase 4	40 participants (Actual)	Interventional	2011-03-31	Completed
Prospective, Double-masked, Randomized, Multi-center, Active-controlled, Parallel-group, 3-month Study Assessing the Safety & Ocular Hypotensive Efficacy of TC-002 Ophthalmic Solution Compared to Latanoprost Ophthalmic Solution 0.005% in Subjects With Ele [NCT05165290]	Phase 3	300 participants (Anticipated)	Interventional	2021-11-29	Active, not recruiting
A 4 Week, Dose-Ranging, Multi-Center, Randomized, Double-Masked, Parallel Study Comparing The Efficacy, Safety, And Tolerability Of Latanoprost 75, 100 And 125 ug/ml To Xalatan In The Treatment Of Primary Open-Angle Glaucoma Aand Ocular Hypertension [NCT01379144]	Phase 2	282 participants (Actual)	Interventional	2003-01-31	Completed
An Open Label, Comparative, Sequential-dose, Multi-centre Study Involving Intracameral Administration of a PA5108 Latanoprost FA SR Ocular Implant Into the Eye of Patients With Mild-moderate Glaucoma [NCT04060758]	Phase 1	40 participants (Anticipated)	Interventional	2020-03-11	Recruiting
A Phase 2, Double-masked, Randomized, Active-controlled, Dose-response Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure [NCT01060579]	Phase 2	217 participants (Actual)	Interventional	2010-02-28	Completed
Phase I Study of Safety and Pharmacokinetics of Once-Daily Topical Solution in Male Subjects With Androgenetic Alopecia [NCT05864885]	Phase 1	14 participants (Anticipated)	Interventional	2023-06-09	Not yet recruiting
Efficacy and Safety of Adding the Brinzolamide/Timolol Maleate Fixed Combination (AZARGA®) to Ocular Hypertensive or Glaucoma Patients Uncontrolled on Prostaglandin Monotherapy [NCT01263444]	Phase 4	47 participants (Actual)	Interventional	2011-03-31	Completed
The Effects of Latanoprost, Bimatoprost and Travoprost on Periocular Skin Pigmentation [NCT00705757]	Phase 4	89 participants (Actual)	Interventional	2008-03-31	Completed
Observational Study Assessing The Efficacy And Tolerability Of Xalatan™ In Patients With Open Angle Glaucoma And /Or Ocular Hypertension. [NCT00950690]		1,289 participants (Actual)	Observational	2005-07-31	Completed
A 2-STAGE, PHASE 2, DOUBLE-MASKED, RANDOMIZED, VEHICLE CONTROLLED, DOSE RESPONSE TRIAL OF PF-04217329 AND THE MARKETED FORMULATION OF LATANOPROST IN PATIENTS WITH PRIMARY OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION [NCT00572455]	Phase 2	318 participants (Actual)	Interventional	2007-12-11	Completed
The International Collaborative Exfoliation Syndrome Treatment Study [NCT00804115]		277 participants (Actual)	Interventional	2000-08-31	Active, not recruiting
A Phase III, Open-label, Single-arm, Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension Who Are Non-/Low-responders to Latanoprost Ophthalmic Solution: FUJ [NCT02822742]	Phase 3	26 participants (Actual)	Interventional	2016-07-02	Completed
A Partially Masked, Phase 2 Study of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension (OH) or Open-Angle Glaucoma (OAG) [NCT00855517]	Phase 2	0 participants (Actual)	Interventional	2009-03-31	Withdrawn(stopped due to Sponsor's decision)
Short-term Effect of Rho-kinase Inhibitor on Retinal Circulation [NCT04234932]	Early Phase 1	10 participants (Anticipated)	Interventional	2020-01-06	Recruiting
Phase IV Clinical Study to Compare the Efficacy of the Krytantek Ofteno PF® Plus Gaap Ofteno PF® Combination to the Krytantek Ofteno PF® Plus Gaap Ofteno PF® Combination, in Primary Open Angle Glaucoma or Ocular Hypertension Patients. [NCT04702789]	Phase 4	28 participants (Actual)	Interventional	2021-10-19	Terminated(stopped due to For interests of sponsor.)
PPL GLAU 13: A Randomized Phase 2 Study of the Effect of Plug Placement on Efficacy and Safety of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension (OH) or Open-Angle Glaucoma (OAG) [NCT01481077]	Phase 2	77 participants (Actual)	Interventional	2011-11-30	Completed
An Open-Label, Randomized, Phase 2 Study of the Effects of Artificial Tears Preserved With Benzalkonium Chloride (AT-BAK) on the Response to the Latanoprost Punctal Plug Delivery System (L PPDS) in Subjects With Ocular Hypertension (OH) or Open-Angle Glau [NCT00845299]	Phase 2	40 participants (Actual)	Interventional	2009-01-31	Completed
A Multicentric, Prospective, Crossover, Double Blind Clinical Study to Evaluate the Non-inferiority of PRO-067 an Ophthlamic Solution Manufactured by Laboratorios Sophia S.A.de C.V., Previous Treatment With GAAP Ofteno ®, in Subjects With Primary Open-ang [NCT02801617]	Phase 3	116 participants (Actual)	Interventional	2015-09-30	Terminated(stopped due to expiration time limit of recruitment)
Comparison of the Effects of Bimatoprost and a Fixed Combination of Latanoprost and Timolol on 24-hour Blood and Ocular Perfusion Pressures [NCT02154217]	Phase 3	200 participants (Actual)	Interventional		Completed
Department of Ophthalmology, Rigshospitalet-Glostrup Valdemar Hansens Vej 13, 2600 Glostrup, Denmark [NCT04957329]	Phase 4	28 participants (Anticipated)	Interventional	2021-09-01	Recruiting
A Randomized, Parallel, Open-label Study to Evaluate Efficacy and Safety Effects Using Mikelan® LA Ophthalmic Solution (OS) 2% Versus Timoptol® XE Ophthalmic Solution (OS) 0.5% in Ocular Hypertension Patients [NCT00972426]	Phase 4	32 participants (Anticipated)	Interventional	2009-10-31	Completed
A 6-month, Randomized, Double-masked Comparison of PhXA41 With Timolol in Patients With Open Angle Glaucoma or Ocular Hypertension. A Multi-centre Study in the United Kingdom [NCT00751049]	Phase 3	294 participants (Actual)	Interventional	1992-12-31	Completed
A 6-month, Randomized, Double-masked Comparison of Latanoprost (PhXA41) With Timolol in Patients With Open Angle Glaucoma or Ocular Hypertension. A Multi-centre Study in the United States. [NCT00751127]	Phase 3	268 participants (Actual)	Interventional	1993-01-31	Completed
24-hour IOP Control With the Travoprost/Timolol Fixed Combination Compared With the Latanoprost/Timolol Fixed Combination, When Both Are Dosed in the Evening in Patients With Exfoliative Glaucoma [NCT00757835]	Phase 4	40 participants (Actual)	Interventional	2008-05-31	Completed
A 6-month, Randomized, Double-masked Comparison of Fixed Combination of Latanoprost and Timolol With the Individual Components, Continuing Into a 6-month Open Label Safety Study of Fixed Combination in Patients With Glaucoma or Ocular Hypertension. A Mult [NCT00800267]	Phase 3	418 participants (Actual)	Interventional	1997-07-31	Completed
Proof of Concept of Latanoprost/Minoxidil (ANR-001.1) Topical Formulation for Eyebrows [NCT05790941]	Early Phase 1	12 participants (Anticipated)	Interventional	2023-03-11	Recruiting
A 12 Week Comparison of DuoTrav and Xalacom at 24 Hours Post-Dose in the Treatment of Open-Angle Glaucoma (the DVX Study) [NCT00887029]	Phase 4	54 participants (Actual)	Interventional	2009-01-31	Completed
Examination of Ocular Surface Effects With Administration of TRAVATAN Z® and XALATAN® [NCT00798759]	Phase 4	236 participants (Actual)	Interventional	2008-12-31	Completed
Dose Response Study of AL-37807 Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension [NCT00465621]	Phase 2	150 participants (Anticipated)	Interventional	2007-03-31	Completed
A Multi-center, Randomized, Blinded Evaluator, Active Control, Parallel, Phase IV Study to Evaluate the Efficacy and Safety of Xalost S in Glaucoma Patients. [NCT04164459]	Phase 4	144 participants (Anticipated)	Interventional	2018-12-19	Recruiting
Pharmacological Intervention Against Diabetic Retinal Flow Disturbances. [NCT00619034]		87 participants (Actual)	Interventional	2007-09-30	Completed
[NCT00872651]	Phase 3	242 participants (Actual)	Interventional	2010-01-31	Completed
Relationship Between Intraocular Pressure Fluctuation and Retinal Ganglion Cell Function in Eyes Receiving Latanoprost 0.005% Versus Placebo [NCT01042665]		82 participants (Actual)	Observational	2006-02-28	Completed
Central Corneal Thickness and 24-hour Fluctuation of Intraocular Pressure [NCT00941525]	Phase 4	174 participants (Actual)	Interventional	2009-09-30	Completed
A 8-WEEK, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP, PHASE III STUDY COMPARING THE EFFICACY AND SAFETY OF XALACOM AND XALATAN IN PATIENTS WITH PRIMARY OPEN ANGLE GLAUCOMA (POAG) OR OCULAR HYPERTENSION (OH) [NCT00383019]	Phase 3	300 participants (Actual)	Interventional	2006-11-14	Completed
Efficacy and Safety of Latanoprost/Timolol Fixed Combination Dosed Twice Daily Compared to Once Daily in Patients With Primary Open Angle Glaucoma [NCT04098861]	Phase 4	40 participants (Anticipated)	Interventional	2019-01-02	Recruiting
Blood Flow of Ophthalmic Artery and Its Relationship to Structural Properties of the Optic Nerve and Intraocular Pressure in Glaucoma [NCT02656979]		125 participants (Anticipated)	Interventional	2013-12-31	Recruiting
An Evaluation of the Ocular Surface Health in Subjects Using TRAVATAN Z® Ophthalmic Solution Versus XALATAN® Ophthalmic Solution [NCT00761319]	Phase 3	705 participants (Actual)	Interventional	2008-10-31	Completed
A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study Evaluating The Efficacy And Safety Of Latanoprost And Timolol In Pediatric Subjects With Glaucoma. [NCT00716859]	Phase 3	139 participants (Actual)	Interventional	2008-07-31	Completed
A Pilot Study on the Effects of Cosopt on IOP Lowering and Ocular Diastolic Perfusion Pressure in Patients Not Controlled With Xalatan Monotherapy [NCT00796198]	Phase 4	50 participants (Anticipated)	Interventional	2008-12-31	Not yet recruiting
Efficacy of Topical Latanoprost 0.005% Verses Timolol 0.5% Demonstrated by Corneal Biomechanical Correcting Modified Goldmann Prism [NCT04178863]	Phase 4	72 participants (Anticipated)	Interventional	2018-07-01	Recruiting
Effects of Latanoprost on Choroidal Blood Flow Regulation in Human Subjects [NCT00712400]		24 participants (Actual)	Interventional	2005-06-30	Completed
A Randomized, Double-masked, Placebo- and Active-controlled, Multi-Center, Dose Escalation Trial of DE-104 Ophthalmic Solution in Japanese and Non-Japanese Subjects With Primary Open-angle Glaucoma or Ocular Hypertension [NCT00868894]	Phase 1/Phase 2	49 participants (Actual)	Interventional	2009-03-31	Completed
A Comparative Analysis of the Effects of Cosopt® Versus Xalacom® on Ocular Hemodynamics and Intraocular Pressure in Patients With Primary Open-angle Glaucoma [NCT00815373]		0 participants (Actual)	Interventional	2008-12-31	Withdrawn(stopped due to no participants recruded.)
A Phase 2, Single-masked, Randomized, Crossover Study Of The 24-hour Intraocular Pressure Lowering And Systemic Exposure of Pf-04217329 Alone And In Combination With Latanoprost [NCT00934089]	Phase 2	31 participants (Actual)	Interventional	2010-01-31	Completed
A 6-month, Randomized, Double-masked Comparison of PhXA41 With Timolol in Patients With Open Angle Glaucoma or Ocular Hypertension. A Multi-centre Study in Scandinavia [NCT00751062]	Phase 3	267 participants (Actual)	Interventional	1992-11-30	Completed
A 28-day Double-masked, Randomized, Parallel-group, Active Controlled Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG) [NCT02083289]	Phase 2	123 participants (Actual)	Interventional	2014-05-31	Completed
A Phase 2 Single-Masked, Randomized Study of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma [NCT02014142]	Phase 2	86 participants (Actual)	Interventional	2013-12-31	Completed
A Phase II Multi-center, Randomized Study to Evaluate the Monocular Addition of Trabodenoson (INO-8875) Ophthalmic Formulation to Latanoprost Ophthalmic Solution Therapy in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma [NCT01917383]	Phase 2	101 participants (Actual)	Interventional	2013-08-31	Completed
An Evaluation of the Ocular Surface Health in Subjects Using TRAVATAN Z® Ophthalmic Solution Versus XALATAN® Ophthalmic Solution [NCT00690794]	Phase 3	726 participants (Actual)	Interventional	2008-07-31	Completed
Comparison of the Effects of Latanoprost and Timolol on Aqueous Humor Dynamics in Ocular Hypertensive Patients [NCT00579969]	Phase 2	30 participants (Actual)	Interventional	2003-12-31	Terminated(stopped due to Study stopped and data not analyzed)
A Comparison of Brinzolamide Ophthalmic Suspension, 1% (Azopt) TID vs. Placebo TID Added to Latanoprost Ophthalmic Solution, 0.005% (Xalatan) in Patients With Elevated IOP on a Prostaglandin [NCT00759941]	Phase 4	86 participants (Actual)	Interventional	2007-10-31	Completed
Ocular Surface Changes With Topical Prostaglandin Analog Therapy [NCT00798694]	Phase 4	58 participants (Actual)	Interventional	2008-11-30	Completed
An 8 Week, Single Masked, Parallel-Group, Exploratory Study Comparing Ocular Surface Signs and Symptoms in Monotherapy Ocular Hypertension or Glaucoma Patients Randomized to Either Xalatan® or Travatan Z® [NCT00799682]	Phase 4	56 participants (Actual)	Interventional	2008-10-31	Completed
[NCT01151904]	Phase 4	17 participants (Actual)	Interventional	2009-11-30	Terminated(stopped due to Difficulty with patient recruitment)
A Randomized, Observer-masked Study of the Safety, Tolerability and Pharmacodynamics of Sequential Ascending 28-Day Repeated Topical Doses of SAR366234 Versus Latanoprost in Patients With Open Angle Glaucoma or Ocular Hypertension [NCT02531152]	Phase 1	54 participants (Actual)	Interventional	2015-09-30	Completed
24-Hour Intraocular Pressure Control Obtained With the Bimatoprost/Timolol Fixed Combination Compared With Latanoprost as First Choice Therapy in Subjects With Exfoliation Syndrome, or Exfoliative Glaucoma [NCT01448837]	Phase 4	37 participants (Actual)	Interventional	2010-04-30	Completed
Determination Of Predictive Factors Allowing To An Additional 10% Reduction Of Intra-Ocular Pressure After A 12-Week Treatment With Latanoprost 0.005% / Timolol 0.5% Fixed Combination (Xalacom) In Previously Treated Patients With Open Angle Glaucoma Or Oc [NCT00230763]	Phase 3	396 participants (Actual)	Interventional	2005-09-30	Completed
Phase 2 Multi-Center, Double-Masked, Randomized, 28-Day Study to Assess the Efficacy, Safety and Tolerability of Single or Twice Daily Doses of AKB-9778 Ophthalmic Solution as an Adjunct to Latanoprost in Patients With Ocular Hypertension (OHT) or Open An [NCT04405245]	Phase 2	194 participants (Actual)	Interventional	2020-06-06	Completed
An 8-Week, Randomized, Open-Label, Parallel Group Study Comparing The Efficacy And Safety Of Xalacom With The Combination Of Unfixed Latanoprost And Timolol In Subjects With Open-Angle Glaucoma Or Ocular Hypertension [NCT00219596]	Phase 3	240 participants	Interventional	2005-06-30	Completed
A Randomized, Double Blind, Placebo-controlled, Parallel Group Study to Determine the Efficacy, the Duration of Action, and Safety of Latanoprost in Patients With Menière's Disease [NCT01973114]	Phase 2	100 participants (Actual)	Interventional	2013-10-31	Active, not recruiting
Intraocular Pressure and Tolerability Study of Preservative Free Bimatoprost 0.03% Unit Dose (BUDPF) or Preservative Free Latanoprost 0.005% Unit Dose (LUDPF) (Monoprost®) in Patients With Ocular Hypertension or Glaucoma: A Randomized, Single Masked, 3 Mo [NCT01975714]	Phase 4	67 participants (Actual)	Interventional	2013-10-31	Completed
Blood-aqueous Barrier Changes After the Use of Timolol and Prostaglandin Analogues Fixed Combination in Pseudophakic Patients With Primary Open Angle Glaucoma [NCT01978015]	Phase 4	69 participants (Actual)	Interventional	2011-10-31	Completed
Safety and Efficacy of Liposomal Latanoprost in Ocular Hypertensive Patients [NCT01987323]	Phase 1/Phase 2	6 participants (Actual)	Interventional	2013-01-31	Completed
Safety and Efficacy Assessment of Geltim LP® 1 mg/g (Unpreserved Timolol Gel - TG1030) in Ocular Hypertensive or Glaucomatous Patients Stabilized by Xalatan® With Ocular Intolerance Signs. [NCT01155219]	Phase 4	150 participants (Actual)	Interventional	2008-07-31	Completed
Efficacy of Topical 5-fluorouracil Versus Topical Latanoprost With Microneedling in Localized Stable Vitiligo: A Randomised Clinical Trial [NCT05513924]	Phase 2/Phase 3	40 participants (Actual)	Interventional	2022-03-15	Completed
Comparison of Bimatoprost and Lataprost in Patients With Chronic Angle-Closure Glaucoma: A Randomized Cross-Over Study [NCT00567788]		60 participants (Anticipated)	Interventional	2006-07-31	Active, not recruiting
The Effects of the Xal-Ease Delivery Aid Device on Patient Compliance With Xalatan Eye Drops [NCT00573638]		50 participants (Anticipated)	Interventional	2005-02-28	Recruiting
Additive Intra-ocular Pressure Reduction Effect of Fixed Combination of Maleate Timolol 0.5%/Dorzolamide 2% on Monotherapy With Latanoprost in Patients With Elevated Intra-ocular Pressure: a Prospective, Four-week, Open-label, Randomized, Controlled Clini [NCT00906594]	Phase 4	56 participants (Actual)	Interventional	2007-09-30	Completed
A Prospective, Unmasked, Randomized Evaluation of the iStent Versus Two Ocular Hypotensive Agents in Patients With Primary Open-Angle Glaucoma [NCT00913029]	Phase 4	192 participants (Actual)	Interventional	2009-05-31	Completed
A Phase III, Randomized, Observer-Masked, Active-Controlled, Parallel-Group, Multicenter Study Assessing the Efficacy and Safety of STN1012600 Ophthalmic Solution 0.002% Compared With Latanoprost 0.005% in Subjects With Primary Open Angle Glaucoma or Ocul [NCT05495061]	Phase 3	325 participants (Actual)	Interventional	2022-08-09	Completed
Open Multicenter Study on the Efficacy of Xalatan at 3 Months as First-line Therapy in Naive Patients With Ocular Hypertension (OH) or Open Angle Glaucoma (OAG), Based on Initial Intraocular Pressure (IOP): 20 mmHg Less Than or Equal to IOP Less Than 24 m [NCT00647101]	Phase 4	600 participants (Actual)	Interventional	2003-12-31	Completed
A Double-masked Randomized Cross-over Study Comparing of the Effect of Xalacom® (Latanoprost/Timolol)and Combigan® (Brimonidine/Timolol) Fixed Combination on Intraocular Pressure and Ocular Blood Flow in Patients With Primary Open Angle Glaucoma or Ocular [NCT00706927]		16 participants (Actual)	Interventional	2006-01-31	Completed
A Randomized, Double-masked, Placebo- and Active- Controlled, Parallel-group, Multi-center, Dose-response Trial of DE-104 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension [NCT00650338]	Phase 2	165 participants (Anticipated)	Interventional	2008-03-31	Completed
Open Label Study to Evaluate the Safety, Tolerability and Biodegradation Period of PA5346 Latanoprost Free Acid (FA) Sustained Release (SR) Ocular Implant When Administered to Patients With Open Angle Glaucoma or Ocular Hypertension [NCT05333419]	Phase 1	6 participants (Anticipated)	Interventional	2022-03-04	Recruiting
An 8 Week Comparison of Xalatan (Latanoprost) to Apo-latanoprost and Co-latanoprost in the Treatment of Open Angle Glaucoma [NCT02792803]	Phase 4	60 participants (Anticipated)	Interventional	2015-09-30	Recruiting
Phase 2 Study of Intraocular Pressure (IOP) Lowering Efficacy of Transdermal Latanoprost Therapy [NCT01426464]	Phase 2	22 participants (Anticipated)	Interventional	2011-09-30	Not yet recruiting
Randomized,Active Comparator-Controlled,Three Months,Open Label Clinical Trial to Compare Efficacy and Safety of Refrigeration-Free Latanoprost (0.005%) and Latanoprost (0.005%) Stored at Refrigeration Temperature in Patients With OAG or OHT [NCT01430923]		30 participants (Anticipated)	Interventional	2011-09-30	Active, not recruiting
A Comparison of Latanoprost (Xalatan) With Travoprost (Travatan) and Bimatoprost (Lumigan) in Patients With Elevated Intraocular Pressure. A Twelve-week, Masked Evaluator, Phase IV, Multicenter Study in the United States. (Xalatan vs Travatan vs Lumigan). [NCT00847483]	Phase 4	375 participants (Actual)	Interventional	2002-01-31	Completed
A 6-Month, Randomized, Double-Masked Comparison Of Fixed Combination Of Latanoprost And Timolol With The Individual Components, Continuing Into A 6-Month Open Label Safety Study Of Fixed Combination In Patients With Glaucoma Or Ocular Hypertension. [NCT00856622]	Phase 3	436 participants (Actual)	Interventional	1997-08-31	Completed
A Phase II/III Randomized, Double-masked, Controlled, Parallel Group, Multicenter Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension -AYAME Study- [NCT02623738]	Phase 2/Phase 3	253 participants (Actual)	Interventional	2015-12-06	Completed
A MULTIPLE-CENTER, INVESTIGATOR/SUBJECT MASKED, ADAPTIVE, MULTIPLE ASCENDING DOSE, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO5093151 FOLLOWING 7 DAYS ADMINISTRATION [NCT02622334]	Phase 1	45 participants (Actual)	Interventional	2015-12-29	Completed
Efficacy and Safety of Latanoprost (Xalatan) and Bimatoprost (Lumigan) Ophthalmic Solutions in Promoting Eyelash Growth in Patients With Alopecia Areata [NCT00187577]		14 participants (Actual)	Interventional	2005-06-30	Completed
A Phase II, Randomized, Observer-masked, Placebo-and Active-controlled, Parallel-group, Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost and Placebo in Subjects With Primary Open-angle Glaucoma o [NCT01868126]	Phase 2	91 participants (Actual)	Interventional	2013-05-31	Completed
Trabeculectomy Versus 2-iStent and Prostaglandin Study [NCT03274323]		0 participants (Actual)	Interventional	2018-01-12	Withdrawn(stopped due to Difficulty obtaining IDE by the FDA. Currently not worthwhile to pursue further.)
[NCT00440141]	Phase 4	40 participants (Actual)	Interventional	2006-07-31	Completed
[NCT00293800]	Phase 3	173 participants (Actual)	Interventional	2004-07-31	Completed
Latanoprost Eluting Contact Lens for Treating Glaucoma and Ocular Hypertension [NCT04500574]	Phase 1	31 participants (Anticipated)	Interventional	2023-04-03	Recruiting
A Phase 2, 28 Day Parallel-Group, Double-Masked, Dose-Finding Study Comparing the Safety and Efficacy of PF-03187207 to Latanoprost [NCT00441883]	Phase 2	176 participants (Actual)	Interventional	2007-03-31	Completed
[NCT00273481]	Phase 4	33 participants	Interventional	2005-09-30	Completed
A 12-Week, Randomized, Double-Masked, Parallel Group Comparison Of Xalacom Given In The Evening, Xalatan Given In The Evening, And Timolol Given In The Morning In Patients With Open Angle Glaucoma Or Ocular Hypertension In The United States. [NCT00277498]	Phase 3	528 participants	Interventional	2005-12-31	Completed
The 24 Control of IOP in Ocular Hypertension: a Cross-over Study on Inflow Versus Outflow Drugs. [NCT01655758]	Phase 4	61 participants (Actual)	Interventional	2002-01-31	Completed
[NCT00287521]	Phase 2	87 participants (Actual)	Interventional	2005-11-30	Completed
A 12-Month Study to Evaluate the Efficacy and Safety of Once-Daily Instillation of Combination Glaucoma Therapy in Patients With Open-Angle Glaucoma or Ocular Hypertension [NCT00311389]	Phase 3	408 participants (Actual)	Interventional	2003-01-31	Completed
An Evaluation of Use of Topical Ocular Hypotensive Medication by Electronic Compliance Measures [NCT00329095]	Phase 4	60 participants	Interventional	2005-12-31	Completed
24-Hour Intraocular Pressure (IOP) And Blood Pressure Control In Glaucoma And Ocular Hypertension Patients [NCT00330577]	Phase 4	30 participants	Interventional	2006-04-30	Completed
Phase 4 Study to Evaluate Efficacy And Safety of Three Different Preparations of Latanoprost 0,005% Eyedrops in Subjects Affected by Primary Open Angle Glaucoma [NCT01580254]	Phase 4	120 participants (Anticipated)	Interventional	2011-06-30	Recruiting
Brimonidine Purite 0.15% Versus Dorzolamide 2% Used as Adjunctive Therapy to Latanoprost [NCT00348400]	Phase 4	0 participants	Interventional		Completed
Effect Of Corneal Versus Conjunctival Delivery On The Corneal Safety, Tolerability, and Antihypertensive Efficacy Of The Xalatan Ophthalmic Delivery Device [NCT00143429]	Phase 2	0 participants (Actual)	Interventional		Withdrawn
Short Term Comparative Study of Xalatan With Benzalkonium Chloride vs. Travatan Z Without Benzalkonium Chloride in Healthy Volunteers [NCT00468988]	Phase 4	30 participants (Anticipated)	Interventional	2007-05-31	Completed
[NCT00539526]	Phase 4	106 participants (Actual)	Interventional	2007-09-30	Completed
[NCT00541242]	Phase 4	586 participants (Actual)	Interventional	2007-12-31	Completed
[NCT00527592]	Phase 4	54 participants (Actual)	Interventional	2007-05-31	Completed
[NCT00716742]		1,099 participants (Actual)	Observational	2004-09-30	Completed
A Multicenter, Open-Label Rocklatan® (Netarsudil/Latanoprost Ophthalmic Solution) 0.02%/0.005% Evaluation of IOP Lowering Efficacy and Safety as Replacement of Current Medical Therapy Regimen for the Reduction of Elevated Intraocular Pressure in Patients [NCT05283395]	Phase 4	136 participants (Actual)	Interventional	2022-03-28	Completed
A 12-Week, Randomized, Double-Masked, Parallel Group Comparison Of Xalacom Given In The Evening, Xalatan Given In The Evening, And Timolol Given In The Morning In Patients With Open Angle Glaucoma Or Ocular Hypertension. [NCT00159653]	Phase 3	500 participants (Actual)	Interventional	2005-07-31	Completed
Comparison of Efficacy of Prostaglandin Analogues (Xalatan) and Aqueous Suppressants (Cosopt) in Reducing Intraocular Pressure Following Selective Laser Trabeculoplasty in the Management of Open-Angle Glaucoma. [NCT00440336]		30 participants	Interventional	2006-10-31	Recruiting
A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Open-Angle Glaucoma or Ocular Hypertension [NCT00051142]	Phase 3	0 participants	Interventional	2001-02-28	Completed
A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Chronic Angle-Closure Glaucoma. [NCT00051181]	Phase 3	0 participants	Interventional	2000-01-31	Completed
Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-angle Glaucoma or Ocular Hypertension Patients [NCT00069706]	Phase 2	118 participants (Actual)	Interventional	2003-07-31	Completed
"A Randomized Post-Marketing Efficacy And Safety Study Of Xalatan Compared With Usual Care Over 36 Months In Patients With Primary Open-Angle Glaucoma, Exfoliative Glaucoma Or Ocular Hypertension" [NCT00140062]	Phase 4	329 participants	Interventional	2002-02-28	Completed
A 4-week Multi-center, Single-masked, Randomized, Latanoprost-controlled, Parallel Group Study to Assess the Efficacy, Tolerability and Safety of RKI983 (0.05% and 0.10%) Ophthalmic Solution Given Twice a Day Versus Once Daily Latanoprost 0.005%, in Patie [NCT00846989]	Phase 1/Phase 2	276 participants (Actual)	Interventional	2009-01-31	Completed
A Prospective, Double-masked, Randomized, Multi-center, Active Controlled, Parallel-group, 3-month Study Assessing the Safety and Ocular Hypotensive Efficacy of PG324 Ophthalmic Solution Compared to AR-13324 Ophthalmic Solution 0.02% and Latanoprost Ophth [NCT02674854]	Phase 3	750 participants (Actual)	Interventional	2016-02-29	Completed
24-hour IOP With DTFC and LTFC Monotherapies and the Adjunctive Therapy of DTFC and Latanoprost in Open-angle Glaucoma Insufficiently Controlled With Latanoprost Monotherapy. [NCT00397241]	Phase 4	33 participants (Actual)	Interventional	2006-09-30	Completed
A Prospective,Randomized,Masked,Study to Evaluate the Interaction of Non-Steroidal Anti-Inflammatory Agent With IOP-Lowering Effect of Brimonidine or Latanoprost. [NCT00402493]		51 participants (Actual)	Interventional	2006-12-31	Completed
A 6-Week Safety and Efficacy Study of TRAVATAN Compared to XALCOM in Subjects With Open-Angle Glaucoma or Ocular Hypertension. [NCT00051155]	Phase 3	0 participants	Interventional	2001-01-31	Completed
Comparing Efficacy and Safety of Combigan With Timolol Adjunctive to Xalatan in Glaucoma or Ocular Hypertension Subjects [NCT00735449]	Phase 4	204 participants (Actual)	Interventional	2008-07-31	Completed
Safety and Efficacy to Reduce the IOP of the Fixed Association of Latanoprost 0.005% (50 μg/mL)/ Brinzolamide 1% (10mg/mL) Drops, Compared to Latanoprost 0.005% (50 μg/mL) Drops, in Patients With Open Angle Glaucoma or Ocular Hypertension [NCT01721707]	Phase 3	0 participants (Actual)	Interventional	2012-12-31	Withdrawn(stopped due to withdrawn by industry)
Prospective, Single Center Switching Study of 0.0015% Tafluprost Ophthalmic Solution in Primary Open-angle Glaucoma and Ocular Hypertension Patients With Corneal Disorders [NCT04737928]		1 participants (Actual)	Interventional	2018-04-02	Completed
[NCT00273429]	Phase 4	0 participants	Interventional	2005-04-30	Completed
A Phase 3, 12-Week, Parallel-Design Study Comparing The Safety, Efficacy, and Ease Of Use Of Xalatan When Self-Administered By Subjects With Open-Angle Glaucoma Or Ocular Hypertension Using Either A Conventional Dropper Bottle Or A Forced-Flow Delivery De [NCT00283764]	Phase 3	0 participants (Actual)	Interventional		Withdrawn
A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension [NCT00293787]	Phase 3	156 participants (Actual)	Interventional	2004-06-30	Completed
[NCT00304785]	Phase 4	36 participants (Anticipated)	Interventional	2005-05-31	Completed
Influence of Travoprost 0.004% and Latanoprost 0.005% on Retinal Vascular Diameter and Choroidal Blood Flow in Glaucoma Patients [NCT00308945]	Phase 4	20 participants (Actual)	Interventional	2003-11-30	Completed
Efficacy of Bimatoprost 0.03% in Patients Who Are Low-Responders to Latanoprost [NCT00347841]	Phase 4	0 participants	Interventional		Completed
A Prospective, Randomized, Controlled Clinical Trial Comparing Topical Medical Therapy With Selective Laser Trabeculoplasty in South Indian Population [NCT01639807]		600 participants (Anticipated)	Interventional	2011-10-31	Recruiting
24-Hour Efficacy of Travoprost/Timolol Benzalkonium Chloride BAK Free Compared With Latanoprost/Timolol Fixed Combination Therapy in Subjects With Open-Angle Glaucoma Insufficiently Controlled With Latanoprost Monotherapy [NCT01779284]	Phase 4	42 participants (Actual)	Interventional	2012-01-31	Completed
A Randomized, Multicenter, Single-Masked, Parallel-Group Dose Finding Study Comparing the Safety and Efficacy of BOL-303259-X to Latanoprost in Subjects With Open Angle Glaucoma or Ocular Hypertension [NCT01223378]	Phase 2	413 participants (Actual)	Interventional	2010-12-13	Completed
In Vivo Effects of Antiglaucomatous Prostaglandin Therapy on Immune Cells, Epithelium, and Nerves of the Ocular Surface: A Laser In Vivo Confocal Microscopy Study [NCT01315574]	Phase 4	14 participants (Actual)	Interventional	2011-02-28	Terminated(stopped due to Slow Enrollment)
Latanoprost Preserved Versus Unpreserved: Effect on Tear Film Thickness as Measured With OCT [NCT02585375]	Phase 4	70 participants (Anticipated)	Interventional	2015-09-17	Recruiting
Efficacy and Safety Assessment of Fixed Combination Unpreserved Latanoprost Eye Drops and Timolol 0.5% (T2347) Versus Xalacom® in Ocular Hypertensive or Glaucomatous Patients. [NCT02278614]	Phase 3	242 participants (Actual)	Interventional	2014-12-31	Completed
The Advantage of Switching From Preserved to Preserved-free Treatments in Glaucoma. A Clinical and Confocal Study. [NCT01433900]	Phase 3	40 participants (Anticipated)	Interventional	2012-05-31	Recruiting
The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients. [NCT01927406]	Phase 4	0 participants (Actual)	Interventional	2014-06-30	Withdrawn(stopped due to Funding source unavailable)
A Prospective, Double-masked, Randomized, Multi-center, Active-controlled, Parallel-group 12-month Study Assessing the Safety and Ocular Hypotensive Efficacy of PG324 Ophthalmic Solution Compared to AR-13324 Ophthalmic Solution, 0.02% and Latanoprost Opht [NCT02558400]	Phase 3	718 participants (Actual)	Interventional	2015-09-18	Completed
[NCT01243567]	Phase 4	81 participants (Actual)	Interventional	2010-06-01	Completed
A Multi Center, Randomized, Double-blind, Parallel Design, Exploratory Trial to Evaluate the Efficacy and Safety of D565H Twice Daily Versus D565 Once Daily in Primary Open Angle Glaucoma or Ocular Hypertension Patients. [NCT03067415]	Phase 2	98 participants (Anticipated)	Interventional	2017-03-30	Recruiting
Phase 3, Randomized, Adaptive Dose-Selection, Multi-regional, Double-Masked, Parallel-Group, 3-Month Trial Evaluating the Safety and Efficacy of NCX 470 vs. Latanoprost 0.005% in Subjects With Open-Angle Glaucoma or Ocular Hypertension (Mont Blanc) [NCT04445519]	Phase 3	670 participants (Actual)	Interventional	2020-06-01	Completed
A Phase 2, Randomized, Multicenter, Masked, Parrallel-Group, Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 (3 Doses: 0.021%, 0.042%, and 0.065%) vs. Latanoprost 0.005% in Subjects With Open-Angle Glaucoma or Ocular Hypertension [NCT03657797]	Phase 2	656 participants (Actual)	Interventional	2018-08-01	Completed
[NCT01525173]	Phase 4	137 participants (Actual)	Interventional	2012-01-31	Completed
Effect of Age on Efficacy and Response Time of Latanoprost 0.005% in Patients With Glaucoma [NCT00224289]	Phase 4	17 participants (Actual)	Interventional	2005-03-31	Completed
Comparison of Efficacy and Ocular Surface Disease Assessment Between Monoprost and BAK-preserved Latanoprost in Glaucoma or Ocular Hypertensive Patients [NCT04743622]	Phase 4	57 participants (Actual)	Interventional	2019-04-30	Completed
An Open-label Comparison of the Safety and Efficacy of Subconjunctival Liposomal Latanoprost (POLAT-001) to Latanoprost Ophthalmic Solution in Patients With Ocular Hypertension and Primary Open Angle Glaucoma [NCT02466399]	Phase 2	80 participants (Actual)	Interventional	2015-07-31	Completed
Comparison of Preserved and Preservative-free Latanoprost 0.005% in Primary Open Angle Glaucoma and Ocular Hypertensive Patients, at Guinness Eye Centre, Lagos. [NCT05606796]	Phase 4	76 participants (Anticipated)	Interventional	2022-12-31	Recruiting
A Pilot, Single-Masked Study to Compare the Safety and Efficacy of ALZ-1101 (Latanoprost 0.005%/Dorzolamide 2.0%) to Latanoprost Ophthalmic Solution, 0.005% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension With Intraocular Pressure Inad [NCT01896180]	Phase 2	63 participants (Actual)	Interventional	2013-07-31	Completed
To Prove the Non-inferiority of Cosopt Compared to Xalatan in the Aspects of Intraocular Pressure and Ocular Perfusion Pressure in Subjects With Normal Tension Glaucoma [NCT01175902]		44 participants (Actual)	Interventional	2011-03-31	Completed
[NCT01253902]	Phase 4	164 participants (Actual)	Interventional	2010-12-31	Completed
Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting [NCT04828057]		50 participants (Actual)	Observational	2021-09-01	Completed
A Randomized, Multicenter, Parallel-Group, Observer-Masked, Phase 3 Study to Compare the Safety and Efficacy of T-2345 Ophthalmic Solution to Xalatan (Latanoprost 0.005%) in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension [NCT02059278]	Phase 3	335 participants (Actual)	Interventional	2014-01-31	Completed
Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01% and Lumigan® 0.03% Unit Dose, in Patients With Primary Open Angle Glaucoma or Ocular Hypertension, Stabilized by Lumigan® 0.01% With Ocular Surface Intolerance [NCT02017327]	Phase 4	379 participants (Actual)	Interventional	2013-12-31	Completed
A Phase IIb, Randomized, Observer-Masked, Placebo- and Active-Controlled, Parallel-Group, Multinational and Multicenter Study Assessing the Safety and Efficacy of DE-126 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertensi [NCT03216902]	Phase 2	241 participants (Actual)	Interventional	2017-07-25	Completed
Effect of Nailfold Application of Latanoprostene Bunod on Nailfold Capillary Blood Flow [NCT03949244]	Phase 4	47 participants (Actual)	Interventional	2019-08-15	Completed
[NCT02105272]	Phase 3	237 participants (Actual)	Interventional	2014-04-30	Completed
A Phase III, Multinational, Multicenter, Investigator-Masked, Randomised, Active-Controlled Trial, Comparing the Efficacy and Safety of DE-130A With Xalatan® in Patients With Open-Angle Glaucoma or Ocular Hypertension [NCT04133311]	Phase 3	386 participants (Actual)	Interventional	2019-04-10	Active, not recruiting
A Phase 2, 28-Day Parallel-Group, Double-Masked, Dose Finding Study Comparing The Safety And Efficacy Of PF-03187207 To Latanoprost In Patients With Primary Open Angle Glaucoma Or Ocular Hypertension. [NCT00595101]	Phase 2	117 participants (Actual)	Interventional	2007-12-31	Completed
[NCT02108288]	Phase 1	30 participants (Actual)	Interventional	2014-04-30	Completed
Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance [NCT04412096]	Phase 4	100 participants (Anticipated)	Interventional	2020-11-23	Recruiting
A Phase 3, Randomized, Multi-Regional, Double-Masked, Parallel-Group Trial Evaluating the Safety and Efficacy of NCX 470 0.1% vs. Latanoprost 0.005% in Subjects With Open-Angle Glaucoma or Ocular Hypertension (Denali) [NCT04630808]	Phase 3	670 participants (Anticipated)	Interventional	2020-11-09	Recruiting
A Phase 2, Double-masked, Randomized, Multi-center, Active-controlled, Dose-response Parallel-group Study Comparing the Safety and Ocular Hypotensive Efficacy of AR-13324 to Latanoprost in Patients With Elevated Intraocular Pressure [NCT01731002]	Phase 2	224 participants (Actual)	Interventional	2012-11-30	Completed
[NCT00811564]	Phase 4	148 participants (Actual)	Interventional	2008-12-31	Completed
A Phase 1/2 Safety and Efficacy Study of JV-GL1 Applied to the Periorbital Skin in Subjects With Open-Angle Glaucoma or Ocular Hypertension [NCT04761705]	Phase 1/Phase 2	70 participants (Anticipated)	Interventional	2021-03-10	Active, not recruiting
A Phase III, Randomized, Observer-Masked, Active-Controlled, Parallel-Group, Multinational and Multicenter Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution 0.002% Compared With Latanoprost Ophthalmic Solution 0.005% in Subjects With O [NCT02981446]	Phase 3	370 participants (Actual)	Interventional	2016-11-30	Completed
Comparison of Benzalkonium Chloride-containing Latanoprost and Preservative-free Bimatoprost on Ocular Surface Disease in Glaucoma Patients: a Prospective Randomised Study [NCT04896125]		300 participants (Anticipated)	Observational	2019-10-02	Recruiting
Multicentric Study to Evaluate the Efficacy and Tolerability of an Innovative Formulation of Benzalkonium Chloride-free Latanoprost in Patients With Primary Open-Angle Glaucoma [NCT03331770]	Phase 4	103 participants (Actual)	Interventional	2017-01-06	Completed
A Randomized Comparative Study of Efficacy and Safety of Topical Latanoprost Versus Topical Corticosteroid in the Treatment of Localized Alopecia Areata [NCT02350023]	Phase 4	50 participants (Actual)	Interventional	2014-09-30	Completed
PPL GLAU 12: A Phase 2 Dose Evaluation Study for the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension (OH) or Open-Angle Glaucoma (OAG) [NCT01481051]	Phase 2	57 participants (Actual)	Interventional	2011-11-30	Completed
Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance [NCT01677507]	Phase 4	135 participants (Actual)	Interventional	2012-08-31	Completed
Effect of Topical Anti-glaucoma Medications on Late Pupillary Light Reflex, as Evaluated by Pupillometry [NCT02522039]		21 participants (Actual)	Interventional	2014-05-31	Completed
Additive Effect of Twice Daily Brinzolamide 1%/Brimonidine 0.2% Fixed Dose Combination as an Adjunctive Therapy to a Prostaglandin Analogue [NCT02419508]	Phase 4	290 participants (Actual)	Interventional	2015-08-07	Completed
A Multi-center, Randomized,Blinded Evaluator, Active Control, Parallel, Phase III Study to Evaluate the Efficacy and Safety of TJO-002 in Primary Open Angle Glaucoma or Ocular Hypertension Patients [NCT03419975]	Phase 3	146 participants (Anticipated)	Interventional	2016-04-26	Completed
A Double-masked, Randomized, Controlled Study Assessing the Safety and Ocular Hypotensive Efficacy of PG324 Ophthalmic Solution, 0.01% and PG324 Ophthalmic Solution, 0.02%, Compared to AR-13324 Ophthalmic Solution, 0.02% and Latanoprost Ophthalmic Solutio [NCT02057575]	Phase 2	298 participants (Actual)	Interventional	2014-01-31	Completed
A Phase III, Multi-center, Randomized, Single-blind (to Evaluator), Parallel, and Positive-controlled Clinical Trial Evaluating the Efficacy and Safety of OPC-1085EL Ophthalmic Solution in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertensio [NCT05583474]	Phase 3	240 participants (Anticipated)	Interventional	2022-09-27	Recruiting
Efficacy and Safety of Prostaglandin Analogue and Carbonic Anhydrase Inhibitor for the Treatment of Pediatric Glaucoma [NCT01527682]	Phase 2	37 participants (Actual)	Interventional	2009-07-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00224289 (2) [back to overview]	Post-Treatment IOP (Intraocular Pressure)
NCT00224289 (2) [back to overview]	Pre-Treatment IOP (Intraocular Pressure)
NCT00383019 (9) [back to overview]	Percent Change of IOP From Baseline to Week 8
NCT00383019 (9) [back to overview]	Number of Subjects With an IOP of <=18 mmHg at Week 8
NCT00383019 (9) [back to overview]	Number of Subjects With an IOP of <=17 mmHg at Week 8
NCT00383019 (9) [back to overview]	Number of Subjects With an IOP of <=16 mmHg at Week 8
NCT00383019 (9) [back to overview]	Number of Subjects With an IOP Reduction of >=3 mmHg From Baseline to Week 8
NCT00383019 (9) [back to overview]	Change of IOP From Baseline to Week 4
NCT00383019 (9) [back to overview]	Change of Intraocular Pressure (IOP) From Baseline to Week 8
NCT00383019 (9) [back to overview]	Number of Subjects With an IOP of <=15 mmHg at Week 8
NCT00383019 (9) [back to overview]	Number of Subjects With an IOP Reduction of >=2 mmHg From Baseline to Week 8
NCT00441883 (3) [back to overview]	Change From Baseline Mean Diurnal Intraocular Pressure (IOP) in the Study Eye on Day 28
NCT00441883 (3) [back to overview]	Percentage of Participants With Intraocular Pressure (IOP) Less Than or Equal to 18 mmHg at Any Visit Through Day 28
NCT00441883 (3) [back to overview]	Change From Baseline in Mean Intraocular Pressure IOP at the Day 7, 14, and 21 Visits
NCT00527592 (1) [back to overview]	Comfort Immediately After Dosing
NCT00539526 (3) [back to overview]	Change From Baseline in Corneal Staining With Fluorescein at Month 3
NCT00539526 (3) [back to overview]	Change From Baseline in Mean Conjunctival Hyperemia Scores at Month 3
NCT00539526 (3) [back to overview]	Change From Baseline in Tear Break-Up Time (TBUT) at Month 3
NCT00541242 (2) [back to overview]	Change From Baseline in Mean Diurnal Intraocular Pressure (IOP) at Week 12
NCT00541242 (2) [back to overview]	Change From Baseline in Mean Diurnal Intraocular Pressure (IOP) at Week 18
NCT00572455 (10) [back to overview]	Number of Participants With Treatment Emergent Ocular Adverse Events (AEs): Stage I
NCT00572455 (10) [back to overview]	Number of Participants With Treatment Emergent Ocular Adverse Events (AEs): Stage II
NCT00572455 (10) [back to overview]	Percentage of Participants Reaching and Maintaining Target Intra Ocular Pressure (IOP): Stage I
NCT00572455 (10) [back to overview]	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II
NCT00572455 (10) [back to overview]	Change From Baseline in Mean Diurnal Intra Ocular Pressure (IOP) in Study Eye at Day 14: Stage I
NCT00572455 (10) [back to overview]	Change From Baseline in Mean Diurnal Intra Ocular Pressure (IOP) in Study Eye at Day 28: Stage II
NCT00572455 (10) [back to overview]	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I
NCT00572455 (10) [back to overview]	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II
NCT00572455 (10) [back to overview]	Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I
NCT00572455 (10) [back to overview]	Percentage of Participants Reaching and Maintaining Target Intra Ocular Pressure (IOP): Stage II
NCT00572936 (8) [back to overview]	Outflow Facility
NCT00572936 (8) [back to overview]	Intraocular Pressure
NCT00572936 (8) [back to overview]	Central Corneal Thickness
NCT00572936 (8) [back to overview]	Blood Pressure
NCT00572936 (8) [back to overview]	Aqueous Flow
NCT00572936 (8) [back to overview]	Episcleral Venous Pressure
NCT00572936 (8) [back to overview]	Anterior Chamber Volume
NCT00572936 (8) [back to overview]	Uvescleral Outflow
NCT00595101 (3) [back to overview]	Change From Baseline Mean Diurnal Intraocular Pressure (IOP) in the Study Eye on Day 28
NCT00595101 (3) [back to overview]	Change From Baseline in Mean Intraocular Pressure (IOP) at Specific Time Points on Day 14 and Day 28
NCT00595101 (3) [back to overview]	Target IOP
NCT00690794 (2) [back to overview]	Percentage of Patients With Corneal Fluorescein Staining Score = 0
NCT00690794 (2) [back to overview]	Mean Change at Day 90 From Baseline (Day 0) in Ocular Surface Disease Index (OSDI) Score
NCT00705757 (1) [back to overview]	The Extent of Latanoprost, Bimatoprost and Travoprost Induced Periocular Skin Hyperpigmentation Over a One Year Time Course in Newly Diagnosed Primary Open Angle and Ocular Hypertension Patients.
NCT00708422 (2) [back to overview]	Mean Change at 12 Weeks (Day 84) From Baseline (Day 0) in Tear Film Break Up Time (TBUT)
NCT00708422 (2) [back to overview]	Mean Change at 12 Weeks (Day 84) From Baseline (Day 0) in Ocular Surface Disease Index (OSDI) Score
NCT00716742 (1) [back to overview]	Change From Baseline in Bilateral Intraocular Pressure (IOP) at One Year
NCT00716859 (10) [back to overview]	Reduction From Baseline in Mean IOP at Week 12 (Observed)
NCT00716859 (10) [back to overview]	Reduction From Baseline in Mean IOP at Week 12, Last Observation Carried Forward (LOCF)
NCT00716859 (10) [back to overview]	Reduction From Baseline in Mean IOP at Week 4
NCT00716859 (10) [back to overview]	Mean IOP at Week 12
NCT00716859 (10) [back to overview]	Mean IOP at Baseline
NCT00716859 (10) [back to overview]	Mean IOP at Week 1
NCT00716859 (10) [back to overview]	Mean IOP at Week 4
NCT00716859 (10) [back to overview]	Percentage of Participants Discontinuing Therapy Due to a Drug-related Adverse Experience
NCT00716859 (10) [back to overview]	Percentage of Participants With Greater Than or Equal to (≥) 15% IOP Reduction From Baseline at Both Weeks 4 and 12
NCT00716859 (10) [back to overview]	Reduction From Baseline in Mean IOP at Week 1
NCT00735449 (5) [back to overview]	Mean Intraocular Pressure (IOP) at 8 AM at Week 6
NCT00735449 (5) [back to overview]	Number of Subjects With Adverse Events
NCT00735449 (5) [back to overview]	Mean Intraocular Pressure (IOP) at 10 AM at Week 12
NCT00735449 (5) [back to overview]	Mean Intraocular Pressure (IOP) at 10 AM at Week 6
NCT00735449 (5) [back to overview]	Mean Intraocular Pressure (IOP) at 8 AM at Week 12
NCT00759941 (4) [back to overview]	Mean Change From Baseline in Intraocular Pressure, 8 AM, at 3 Months
NCT00759941 (4) [back to overview]	Mean Change From Baseline in Intraocular Pressure, 12 PM, at 3 Months
NCT00759941 (4) [back to overview]	Mean Change From Baseline in Intraocular Pressure, 4 PM, at 3 Months
NCT00759941 (4) [back to overview]	Mean Change From Baseline in Intraocular Pressure, Diurnal, at 3 Months
NCT00761319 (2) [back to overview]	Mean Change at Day 90 From Baseline (Day 0) in Ocular Surface Disease Index (OSDI) Score
NCT00761319 (2) [back to overview]	Percentage of Patients With Corneal Fluorescein Staining Score = 0
NCT00798694 (6) [back to overview]	Change in Tear Break up Time (TBUT)
NCT00798694 (6) [back to overview]	Conjunctival Hyperemia Score
NCT00798694 (6) [back to overview]	Corneal Staining Score
NCT00798694 (6) [back to overview]	Intraocular Pressure
NCT00798694 (6) [back to overview]	Ocular Surface Disease Index Score
NCT00798694 (6) [back to overview]	Tear Production
NCT00798759 (2) [back to overview]	Mean Change at 12 Weeks (Day 84) From Baseline (Day 0) in Tear Film Break-Up Time (TFBUT)
NCT00798759 (2) [back to overview]	Mean Change at 12 Weeks (Day 84) From Baseline (Day 0) in Ocular Surface Disease Index (OSDI) Score
NCT00811564 (1) [back to overview]	Intraocular Pressure (IOP) at Week 12
NCT00934089 (30) [back to overview]	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 14: 4 PM (8 Hours)
NCT00934089 (30) [back to overview]	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 14: 6 PM (10 Hours)
NCT00934089 (30) [back to overview]	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 14: 8 Ante Meridiem (AM) (0 Hour)
NCT00934089 (30) [back to overview]	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 14: 8 PM (12 Hours)
NCT00934089 (30) [back to overview]	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 15: 4 AM (20 Hours)
NCT00934089 (30) [back to overview]	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 15: 6 AM (22 Hours)
NCT00934089 (30) [back to overview]	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 15: 8 AM (24 Hours)
NCT00934089 (30) [back to overview]	Change From Baseline in Total Corneal Staining Score at Day 7, 13, 16, 21, 28 and 35
NCT00934089 (30) [back to overview]	Diastolic Ocular Perfusion Pressure (DOPP)
NCT00934089 (30) [back to overview]	Maximum Conjunctival Hyperemia Score
NCT00934089 (30) [back to overview]	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 15: 12 AM (16 Hours)
NCT00934089 (30) [back to overview]	Total Corneal Staining Score
NCT00934089 (30) [back to overview]	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 16: 8 AM (48 Hours)
NCT00934089 (30) [back to overview]	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 17: 8 AM (72 Hours)
NCT00934089 (30) [back to overview]	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 21: 8 AM (168 Hours)
NCT00934089 (30) [back to overview]	Number of Participants With Ocular and Systemic Adverse Events (AEs)
NCT00934089 (30) [back to overview]	Plasma Concentration for PF-04217329 Active Metabolite (CP-544326) at 0.25 Hours on Day 14
NCT00934089 (30) [back to overview]	Plasma Concentration for PF-04217329 Active Metabolite (CP-544326) at 0.5 Hours on Day 14
NCT00934089 (30) [back to overview]	Plasma Concentration for PF-04217329 Active Metabolite (CP-544326) at 0.75 Hours on Day 14
NCT00934089 (30) [back to overview]	Plasma Concentration for PF-04217329 Active Metabolite (CP-544326) at 1 Hour on Day 14
NCT00934089 (30) [back to overview]	Plasma Concentration for PF-04217329 Active Metabolite (CP-544326) at 5 Minutes on Day 14
NCT00934089 (30) [back to overview]	Change From Baseline in Corneal Endothelial Cell Counts at Day 13 and 35
NCT00934089 (30) [back to overview]	Change From Baseline in Corneal Thickness at Day 7, 13, 16, 21, 28 and 35
NCT00934089 (30) [back to overview]	Change From Baseline in Diastolic Ocular Perfusion Pressure (DOPP) at Day 14 (8 AM, 10 AM, 12 PM, 2 PM, 4 PM, 6 PM, 8 PM, 10 PM) and Day 15 (12 AM, 2 AM, 4 AM, 6 AM and 8 AM)
NCT00934089 (30) [back to overview]	Change From Baseline in Maximum Conjunctival Hyperemia Score Observed
NCT00934089 (30) [back to overview]	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 14: 10 AM (2 Hours)
NCT00934089 (30) [back to overview]	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 14: 10 PM (14 Hours)
NCT00934089 (30) [back to overview]	Percentage of Participants With Photophobia and Iritis
NCT00934089 (30) [back to overview]	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 14: 12 Post Meridiem (PM) (4 Hours)
NCT00934089 (30) [back to overview]	Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 14: 2 PM (6 Hours)
NCT01155219 (1) [back to overview]	Ocular Tolerance
NCT01175902 (6) [back to overview]	Blood Pressure (BP), Period 1
NCT01175902 (6) [back to overview]	Blood Pressure (BP), Period 2
NCT01175902 (6) [back to overview]	Intraocular Pressure (IOP), Period 2
NCT01175902 (6) [back to overview]	Ocular Perfusion Pressure (OPP), Period 1
NCT01175902 (6) [back to overview]	OPP, Period 2
NCT01175902 (6) [back to overview]	Intraocular Pressure (IOP), Period 1
NCT01191008 (3) [back to overview]	Number of Participants With Treatment-Related Adverse Events Unexpected From Japanese Package Insert
NCT01191008 (3) [back to overview]	Clinical Effectiveness Rate
NCT01191008 (3) [back to overview]	Number of Participants WithTreatment-Related Adverse Events
NCT01223378 (5) [back to overview]	Change in IOP at Specified Time Points (8 AM, 12 PM, 4 PM) at Visit 6 (Day 28)
NCT01223378 (5) [back to overview]	Change in Mean Diurnal IOP at Visits 4,5, and 7
NCT01223378 (5) [back to overview]	IOP
NCT01223378 (5) [back to overview]	Change in IOP at Specified Time Points (8 AM, 12 PM, 4 PM) at Visits 4, 5, and 7 (Days 7, 14, and 29)
NCT01223378 (5) [back to overview]	Change in Mean Diurnal IOP at Visit 6 (Day 28)
NCT01243567 (5) [back to overview]	Change From Baseline IOP
NCT01243567 (5) [back to overview]	Absolute Difference Between Patient's Highest IOP Reading at Baseline (Day 0) and the Corresponding IOP Reading
NCT01243567 (5) [back to overview]	Absolute Difference Between Patient's Lowest IOP Reading at Baseline (Day 0) and the Corresponding IOP Reading
NCT01243567 (5) [back to overview]	Change From Baseline in Average Intraocular Pressure (IOP)
NCT01243567 (5) [back to overview]	Percentage of Patients Reaching a Predefined Target Pressure Threshold
NCT01253902 (3) [back to overview]	Mean Tear Break Up Time (TBUT) at Week 12
NCT01253902 (3) [back to overview]	Mean Corneal Staining With Fluorescein at Week 12
NCT01253902 (3) [back to overview]	Mean Conjunctival Hyperemia at Week 12
NCT01263444 (4) [back to overview]	Percentage of Patients Reaching the Target IOP (≤ 18 mmHg)
NCT01263444 (4) [back to overview]	Mean Change From Baseline in IOP at Week 4
NCT01263444 (4) [back to overview]	Mean Change From Baseline in Intraocular Pressure (IOP) at Week 12
NCT01263444 (4) [back to overview]	Mean Change From Baseline in IOP Per Prostaglandin Group at Week 12
NCT01315574 (3) [back to overview]	Effectiveness in Lowering Intraocular Pressure
NCT01315574 (3) [back to overview]	Corneal Fluorescein Staining Score
NCT01315574 (3) [back to overview]	Tear Film Break-Up Time
NCT01525173 (1) [back to overview]	Change From Baseline in Mean Diurnal Intraocular Pressure (IOP)
NCT01527682 (3) [back to overview]	Time to Treatment Failure (TTF)
NCT01527682 (3) [back to overview]	Number of Eyes With an Adverse Event (AE)
NCT01527682 (3) [back to overview]	Percentage of Eyes With Response
NCT01677507 (3) [back to overview]	Variation in Episcleral Venous Pressure.
NCT01677507 (3) [back to overview]	Variation in Aqueous Flow Between Individuals.
NCT01677507 (3) [back to overview]	Variation in Eye Pressure Between Individuals.
NCT01731002 (2) [back to overview]	Intraocular Pressure (IOP)
NCT01731002 (2) [back to overview]	Extent of Exposure
NCT02057575 (1) [back to overview]	Intraocular Pressure (IOP)
NCT02059278 (5) [back to overview]	Visual Acuity
NCT02059278 (5) [back to overview]	Intraocular Pressure
NCT02059278 (5) [back to overview]	Mean Deviation in Visual Field
NCT02059278 (5) [back to overview]	Ophthalmoscopy
NCT02059278 (5) [back to overview]	Slit Lamp Examination
NCT02105272 (6) [back to overview]	Decrease From Baseline in Intraocular Pressure at Week 8 at 2 Hours After IMP Administration
NCT02105272 (6) [back to overview]	Decrease From Baseline in Intraocular Pressure at Week 8 at 8 Hours After IMP Administration
NCT02105272 (6) [back to overview]	Intraocular Pressure at Week 8 at 2 Hours After IMP Administration
NCT02105272 (6) [back to overview]	Decrease From Baseline in Intraocular Pressure
NCT02105272 (6) [back to overview]	Intraocular Pressure at Week 8 Predose
NCT02105272 (6) [back to overview]	Intraocular Pressure at Week 8 at 8 Hours After IMP Administration
NCT02108288 (4) [back to overview]	Cmax of Carteolol
NCT02108288 (4) [back to overview]	Tmax of Latanoprost Acid
NCT02108288 (4) [back to overview]	Tmax of Carteolol
NCT02108288 (4) [back to overview]	Cmax of Latanoprost Acid
NCT02278614 (1) [back to overview]	Non-inferiority of T2347 Compared With Xalacom® on Change in Mean IOP at 9.00 am (± 1 Hour) Between the Baseline (Day 0) and Day 84 in the Worse Eye
NCT02419508 (7) [back to overview]	Mean Percentage Change From Baseline in IOP at 11:00 at Week 6
NCT02419508 (7) [back to overview]	Mean Change From Baseline in IOP at 09:00 at Week 6
NCT02419508 (7) [back to overview]	Mean Change From Baseline in IOP at 11:00 at Week 6
NCT02419508 (7) [back to overview]	Mean Diurnal IOP at Week 6
NCT02419508 (7) [back to overview]	Mean Percentage Change From Baseline at 09:00 at Week 6
NCT02419508 (7) [back to overview]	Mean Percentage Change From Baseline in Diurnal IOP at Week 6
NCT02419508 (7) [back to overview]	Mean Change From Baseline (on PGA) in Diurnal IOP (Mean of 09:00 and 11:00 Time Points) at Week 6
NCT02466399 (1) [back to overview]	Mean Change in Intraocular Pressure Between Two Measures- Baseline and 3 Months
NCT02558400 (2) [back to overview]	Extent of Exposure
NCT02558400 (2) [back to overview]	Intraocular Pressure (IOP)
NCT02674854 (1) [back to overview]	Intraocular Pressure (IOP)
NCT02801617 (7) [back to overview]	Number of Adverse Events.
NCT02801617 (7) [back to overview]	Percentage of Participants With Chemosis
NCT02801617 (7) [back to overview]	Percentage of Ocular Burning
NCT02801617 (7) [back to overview]	Percentage of Participants With Foreign Body Sensation
NCT02801617 (7) [back to overview]	Percentage of Participants With Hyperemia
NCT02801617 (7) [back to overview]	Percentage of Participants With Tearing
NCT02801617 (7) [back to overview]	Target Intraocular Pressure (TIOP)
NCT02829996 (1) [back to overview]	Mean Intraocular Pressure (IOP)
NCT03216902 (12) [back to overview]	Percentage of Subjects With Mean Diurnal Intraocular Pressure ≤ 18 mmHg in the Study Eye at Each Post-baseline Visit
NCT03216902 (12) [back to overview]	Percentage of Subjects With Mean Diurnal Intraocular Pressure Reduction From Baseline ≥ 20%, 25% and 30% in the Study Eye at Each Post-baseline Visit
NCT03216902 (12) [back to overview]	Percentage of Subjects With Mean Diurnal Intraocular Pressure Reduction From Baseline ≥ 20%, 25% and 30% in the Study Eye at Each Post-baseline Visit
NCT03216902 (12) [back to overview]	Intraocular Pressure in the Study Eye at Month 3
NCT03216902 (12) [back to overview]	Intraocular Pressure in the Study Eye at Week 1 and Week 2
NCT03216902 (12) [back to overview]	Intraocular Pressure in the Study Eye at Week 6
NCT03216902 (12) [back to overview]	Mean Diurnal Intraocular Pressure in the Study Eye at Each Post-baseline Visit
NCT03216902 (12) [back to overview]	Percent Change From Baseline (CFB) in Intraocular Pressure in the Study Eye at Three Time Points at Each Post-baseline Visit
NCT03216902 (12) [back to overview]	Percent Change From Baseline (CFB) in Mean Diurnal Intraocular Pressure in the Study Eye at Each Post-baseline Visit
NCT03216902 (12) [back to overview]	Percentage of Subjects With Mean Diurnal Intraocular Pressure ≤ 18 mmHg in the Study Eye at Each Post-baseline Visit
NCT03216902 (12) [back to overview]	Change From Baseline (CFB) in Intraocular Pressure in the Study Eye at Three Time Points at Each Post-baseline Visit
NCT03216902 (12) [back to overview]	Change From Baseline (CFB) in Mean Diurnal Intraocular Pressure in the Study Eye at Each Post-baseline Visit
NCT03284853 (1) [back to overview]	Mean Diurnal Intraocular Pressure by Goldmann Applanation Tonometry
NCT03657797 (3) [back to overview]	Change From Baseline in Study Eye Mean Diurnal IOP at Week 1, Week 2, and Exit Visit
NCT03657797 (3) [back to overview]	Percentage of Subjects With Treatment-emergent Ocular Adverse Events
NCT03657797 (3) [back to overview]	Change From Baseline in Study Eye Mean Diurnal IOP at the Week 4
NCT03949244 (1) [back to overview]	NFC Blood Flow at Baseline and 15 Minutes
NCT04405245 (9) [back to overview]	Change From Baseline in Intraocular Pressure at Day 28 (Study Eye)
NCT04405245 (9) [back to overview]	Mean Change From Baseline in Diurnal Mean IOP at the Day 14 Visit (Study Eye)
NCT04405245 (9) [back to overview]	Percentages of Subjects Achieving Pre-Specified Mean, Mean Change, and Percent Mean Change in Diurnal Mean IOP Levels
NCT04405245 (9) [back to overview]	Mean Percent Change From Diurnally Adjusted Baseline IOP at Each Time Point on Days 14 and 28
NCT04405245 (9) [back to overview]	Mean Change From Baseline in Diurnal Mean IOP on Days 14 and 28 (Both Eyes)
NCT04405245 (9) [back to overview]	Mean Percent Change From Baseline in Diurnal Mean IOP on Days 14 and 28
NCT04405245 (9) [back to overview]	Mean Observed IOP at Each Time Point on Days 14 and 28
NCT04405245 (9) [back to overview]	Observed Mean Diurnal Mean IOP on Days 14 and 28 (Both Eyes)
NCT04405245 (9) [back to overview]	Mean Change From Baseline IOP at Each Time Point on Days 14 and 28

Post-Treatment IOP (Intraocular Pressure)

Subjects applied topical latanoprost at bedtime for 8 weeks (NCT00224289)
Timeframe: 8 Weeks

Intervention	mm Hg (Mean)
Topical Latanoprost	18.3

Intervention	mmHg (milimeters of mercury) (Mean)
PF-03187207 0.024% AM	-6.96
PF-03187207 0.040% AM	-7.09
PF-03187207 0.040% PM	-8.20
Latanoprost 0.005% AM	-6.02
Latanoprost 0.005% PM	-7.28

Intervention	mmHg (milimeters of mercury) (Mean)
	Day 7	Day 14	Day 21
Latanoprost 0.005% AM	-5.49	-5.27	-5.81
Latanoprost 0.005% PM	-6.82	-7.0	-7.04
PF-03187207 0.024% AM	-6.58	-7.20	-6.68
PF-03187207 0.040% AM	-7.20	-7.20	-7.34
PF-03187207 0.040% PM	-7.85	-8.18	-8.35

Intervention	Scores on a Scale (Mean)
	Baseline	Month 3
Bimatoprost 0.03%	0.59	0.15
Latanoprost 0.005%	0.70	-0.18
Travoprost 0.004%	0.48	-0.07

Intervention	millimeters of mercury (mmHg) (Mean)
	Baseline	Week 12
Bimatoprost 0.03% Eye Drops	21.90	-5.64
Latanoprost 0.005% Eye Drops	22.16	-4.89

Intervention	millimeters of mercury (mmHg) (Mean)
	Baseline	Week 18
Bimatoprost 0.03% Eye Drops	21.90	-5.77
Latanoprost 0.005% Eye Drops	22.16	-5.09

Intervention	Participants (Count of Participants)
Taprenepag 0.0025% (Stage I)	1
Taprenepag 0.005% (Stage I)	2
Taprenepag 0.01% (Stage I)	0
Taprenepag 0.015% (Stage I)	5
Taprenepag 0.02% (Stage I)	4
Taprenepag 0.03% (Stage I)	9
Taprenepag Vehicle (Stage I)	3

Intervention	Participants (Count of Participants)
Latanoprost Vehicle and Taprenepag 0.005% (Stage II)	17
Latanoprost Vehicle and Taprenepag 0.01% (Stage II)	20
Latanoprost Vehicle and Taprenepag 0.015% (Stage II)	27
Latanoprost 0.005% and Taprenepag 0.005% (Stage II)	24
Latanoprost 0.005% and Taprenepag 0.01% (Stage II)	26
Latanoprost 0.005% and Taprenepag 0.015% (Stage II)	26
Latanoprost 0.005% and Taprenepag Vehicle (Stage II)	14

Intervention	percentage of participants (Number)
Taprenepag 0.0025% (Stage I)	0.0
Taprenepag 0.005% (Stage I)	11.1
Taprenepag 0.01% (Stage I)	11.1
Taprenepag 0.015% (Stage I)	0.0
Taprenepag 0.02% (Stage I)	11.1
Taprenepag 0.03% (Stage I)	22.2
Taprenepag Vehicle (Stage I)	0.0

Intervention	mmHg (Mean)
	Day 0: Baseline for Day 1: 8AM	Day 0: Baseline for Day 7,14,28: 8AM	Day 0: Baseline for Day 7: 10AM	Day 0: Baseline for Day 7: 1PM	Day 0: Baseline for Day 7: 4PM	Day 0: Baseline for Day 14: 10AM	Day 0: Baseline for Day 14: 1PM	Day 0: Baseline for Day 14: 4PM	Day 0: Baseline for Day 28: 10AM	Day 0: Baseline for Day 28: 1PM	Day 0: Baseline for Day 28: 4PM	Change at Day 1: 8AM	Change at Day 7: 8AM	Change at Day 7: 10AM	Change at Day 7: 1PM	Change at Day 7: 4PM	Change at Day 14: 8AM	Change at Day 14: 10AM	Change at Day 14: 1PM	Change at Day 14: 4PM	Change at Day 28: 8AM	Change at Day 28: 10AM	Change at Day 28: 1PM	Change at Day 28: 4PM
Latanoprost 0.005% and Taprenepag 0.005% (Stage II)	29.10	29.03	27.13	26.04	25.92	26.94	25.92	25.99	27.06	25.98	26.00	9.72	10.20	9.19	8.02	8.27	9.50	7.95	7.03	7.33	9.92	8.68	7.51	6.94
Latanoprost 0.005% and Taprenepag 0.01% (Stage II)	28.63	28.63	26.42	25.34	25.35	26.42	25.34	25.35	26.42	25.34	25.35	9.87	11.22	9.61	8.54	8.44	10.94	9.76	8.83	8.36	10.66	9.55	8.66	8.23
Latanoprost 0.005% and Taprenepag 0.015% (Stage II)	29.19	29.19	27.48	26.27	26.12	27.41	26.21	26.20	27.41	26.21	26.20	9.49	10.91	10.14	9.17	8.55	10.52	9.56	8.86	7.95	10.20	9.74	8.82	7.64
Latanoprost 0.005% and Taprenepag Vehicle (Stage II)	28.55	28.60	26.70	25.99	25.84	26.70	25.99	25.84	26.70	25.99	25.84	8.16	8.50	7.60	6.69	6.14	8.94	7.30	7.16	6.30	7.91	7.06	6.66	5.79
Latanoprost Vehicle and Taprenepag 0.005% (Stage II)	27.34	27.59	25.74	24.85	24.83	25.70	24.84	24.87	25.70	24.84	24.87	8.22	9.24	8.47	7.60	7.57	8.74	7.89	6.89	7.46	7.99	7.78	6.54	7.09
Latanoprost Vehicle and Taprenepag 0.01% (Stage II)	28.21	28.16	26.44	25.67	25.59	26.44	25.67	25.59	26.44	25.67	25.59	6.29	8.76	7.49	6.99	6.92	8.60	6.83	6.33	6.24	8.40	7.00	6.47	6.51
Latanoprost Vehicle and Taprenepag 0.015% (Stage II)	28.27	28.27	26.70	26.19	25.87	26.66	26.13	25.86	26.66	26.13	25.86	7.66	8.59	8.10	7.46	7.60	8.55	7.22	7.17	7.55	8.00	6.92	7.07	6.74

Intervention	mmHg (Mean)
	Baseline	Change at Day 14
Taprenepag 0.0025% (Stage I)	25.97	3.65
Taprenepag 0.005% (Stage I)	26.25	5.40
Taprenepag 0.01% (Stage I)	25.90	7.18
Taprenepag 0.015% (Stage I)	26.44	6.48
Taprenepag 0.02% (Stage I)	28.10	6.00
Taprenepag 0.03% (Stage I)	26.26	6.69
Taprenepag Vehicle (Stage I)	26.04	0.64

Intervention	percent change (Least Squares Mean)
KP2035 Group	-12.67
Xalatan Group	-7.69

Intervention	mmHg (Least Squares Mean)
KP2035 Group	-2.50
Xalatan Group	-1.17

Intervention	mmHg (Least Squares Mean)
KP2035 Group	-2.59
Xalatan Group	-1.62

Intervention	Units on a scale (Mean)
Travoprost	7.8
Latanoprost	7.1

Intervention	mmHg (Mean)
	Baseline	Change at Day 28
Latanoprost 0.005% and Taprenepag 0.005% (Stage II)	26.98	8.29
Latanoprost 0.005% and Taprenepag 0.01% (Stage II)	26.36	9.10
Latanoprost 0.005% and Taprenepag 0.015% (Stage II)	27.34	8.78
Latanoprost 0.005% and Taprenepag Vehicle (Stage II)	26.81	6.74
Latanoprost Vehicle and Taprenepag 0.005% (Stage II)	25.75	7.35
Latanoprost Vehicle and Taprenepag 0.01% (Stage II)	26.47	7.05
Latanoprost Vehicle and Taprenepag 0.015% (Stage II)	26.69	7.14

Intervention	mmHg (Mean)
	Day0: Baseline for Day 1, 7, 14 8 AM	Day 0: Baseline for Day 7 10 AM	Day 0: Baseline for Day 7 1 PM	Day 0: Baseline for Day 7 4 PM	Day 0:Baseline for Day 14 10 AM	Day 0:Baseline for Day 14 1 PM	Day 0:Baseline for Day 14 4 PM	Change at Day 1 8 AM	Change at Day 7 8 AM	Change at Day 7 10 AM	Change at Day 7 1 PM	Change at Day 7 4 PM	Change at Day 14 8 AM	Change at Day 14 10 AM	Change at Day 14 1 PM	Change at Day 14 4 PM
Taprenepag 0.0025% (Stage I)	27.78	24.75	25.83	25.50	24.75	25.83	25.50	4.89	4.56	3.58	4.67	4.33	3.44	3.86	4.56	2.72
Taprenepag 0.005% (Stage I)	27.72	26.11	26.06	25.11	26.11	26.06	25.11	5.44	6.67	7.00	6.22	5.06	6.11	6.33	5.22	3.94
Taprenepag 0.01% (Stage I)	27.72	25.94	25.08	24.86	25.94	25.08	24.86	7.72	8.28	7.56	7.86	7.25	8.44	7.67	6.53	6.08
Taprenepag 0.015% (Stage I)	28.45	26.30	25.10	25.90	26.30	25.10	25.90	6.75	8.20	7.15	7.55	8.95	7.70	6.40	5.50	6.30
Taprenepag 0.02% (Stage I)	29.81	26.53	27.13	26.41	27.44	28.03	27.11	7.75	9.58	6.16	6.50	5.53	6.86	5.56	5.14	6.44
Taprenepag 0.03% (Stage I)	28.44	26.16	25.69	25.28	26.16	25.69	25.28	7.22	7.67	8.72	7.44	6.66	8.28	8.09	7.19	6.22
Taprenepag Vehicle (Stage I)	28.15	25.13	25.52	25.35	25.13	25.52	25.35	1.35	2.15	-0.33	1.90	-0.23	1.56	0.67	0.06	0.27

Intervention	mmHg (Mean)
	Day 1: 8 AM	Day 7: 8 AM	Day 7: 10 AM	Day 7: 1 PM	Day 7: 4 PM	Day 14: 8 AM	Day 14: 10 AM	Day 14: 1 PM	Day 14: 4 PM	Day 28: 8 AM	Day 28: 10 AM	Day 28: 1 PM	Day 28: 4 PM
Latanoprost 0.005% and Taprenepag 0.005% (Stage II)	19.39	18.83	17.94	18.02	17.65	19.53	18.98	18.89	18.66	19.11	18.38	18.47	19.06
Latanoprost 0.005% and Taprenepag 0.01% (Stage II)	18.76	17.41	16.80	16.80	16.91	17.69	16.66	16.52	16.98	17.97	16.86	16.68	17.12
Latanoprost 0.005% and Taprenepag 0.015% (Stage II)	19.69	18.28	17.34	17.09	17.56	18.67	17.85	17.35	18.26	18.99	17.67	17.39	18.56
Latanoprost 0.005% and Taprenepag Vehicle (Stage II)	20.39	20.10	19.10	19.30	19.70	19.66	19.40	18.83	19.54	20.69	19.64	19.33	20.06
Latanoprost Vehicle and Taprenepag 0.005% (Stage II)	19.12	18.34	17.26	17.25	17.26	18.85	17.81	17.94	17.41	19.60	17.93	18.30	17.79
Latanoprost Vehicle and Taprenepag 0.01% (Stage II)	21.91	19.40	18.96	18.68	18.67	19.56	19.61	19.33	19.35	19.76	19.44	19.19	19.08
Latanoprost Vehicle and Taprenepag 0.015% (Stage II)	20.61	19.68	18.61	18.73	18.27	19.72	19.44	18.96	18.31	20.28	19.74	19.06	19.13

Intervention	percentage of participants (Number)
Latanoprost Vehicle and Taprenepag 0.005% (Stage II)	22.9
Latanoprost Vehicle and Taprenepag 0.01% (Stage II)	2.8
Latanoprost Vehicle and Taprenepag 0.015% (Stage II)	13.9
Latanoprost 0.005% and Taprenepag 0.005% (Stage II)	8.3
Latanoprost 0.005% and Taprenepag 0.01% (Stage II)	38.9
Latanoprost 0.005% and Taprenepag 0.015% (Stage II)	16.7
Latanoprost 0.005% and Taprenepag Vehicle (Stage II)	5.7

Intervention	µL/min per mm Hg (Mean)
	day time fluorophotometry	daytime tonography	night tonography
Dorzolamide	0.21	0.20	0.18
Latanoprost	0.23	0.22	0.21
Timolol	0.23	0.18	0.17

Intervention	mmHg (Mean)
	Daytime	Night time
Dorzolamide	20.2	17.6
Latanoprost	17.6	17.0
Timolol	16.4	17.1

Intervention	μm (Mean)
	day time	night time
Dorzolamide	564	582
Latanoprost	564	585
Timolol	568	586

Intervention	mmHg (Mean)
	systolic day time	systolic night time	diastolic day time	diastolic night time
Dorzolamide	139	138	83	82
Latanoprost	136	143	78	83
Timolol	138	136	81	79

Intervention	mmHg (milimeters of mercury) (Mean)
PF-0318 0.006%	-5.12
PF-0318 0.024%	-5.94
PF-0318 0.04%	-5.02
0.005% Latanoprost	-5.25

Intervention	mmHg (milimeters of mercury) (Mean)
	Day 14, 9am	Day 28, 9am	Day 28, 11am	Day 28, 2pm	Day 28, 5pm
0.005% Latanoprost	-5.53	-5.33	-5.65	-5.27	-4.73
PF-0318 0.006%	-5.20	-5.63	-5.61	-4.57	-4.68
PF-0318 0.024%	-5.87	-6.11	-6.07	-5.28	-6.28
PF-0318 0.04%	-4.35	-5.19	-5.46	-4.85	-4.57

latanoprost

Description

Cross-References

Synonyms (105)

Research Excerpts

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (4)

Drug Classes (3)

Protein Targets (10)

Potency Measurements

Inhibition Measurements

Biological Processes (43)

Molecular Functions (26)

Ceullar Components (18)

Bioassays (41)

Research

Studies (1,442)

Study Types

Clinical Trials (211)

Trial Overview

Trial Outcomes

Post-Treatment IOP (Intraocular Pressure)

Pre-Treatment IOP (Intraocular Pressure)

Percent Change of IOP From Baseline to Week 8

Number of Subjects With an IOP of <=18 mmHg at Week 8

Number of Subjects With an IOP of <=17 mmHg at Week 8

Number of Subjects With an IOP of <=16 mmHg at Week 8

Number of Subjects With an IOP Reduction of >=3 mmHg From Baseline to Week 8

Change of IOP From Baseline to Week 4

Change of Intraocular Pressure (IOP) From Baseline to Week 8

Number of Subjects With an IOP of <=15 mmHg at Week 8

Number of Subjects With an IOP Reduction of >=2 mmHg From Baseline to Week 8

Change From Baseline Mean Diurnal Intraocular Pressure (IOP) in the Study Eye on Day 28

Percentage of Participants With Intraocular Pressure (IOP) Less Than or Equal to 18 mmHg at Any Visit Through Day 28

Change From Baseline in Mean Intraocular Pressure IOP at the Day 7, 14, and 21 Visits

Comfort Immediately After Dosing

Change From Baseline in Corneal Staining With Fluorescein at Month 3

Change From Baseline in Mean Conjunctival Hyperemia Scores at Month 3

Change From Baseline in Tear Break-Up Time (TBUT) at Month 3

Change From Baseline in Mean Diurnal Intraocular Pressure (IOP) at Week 12

Change From Baseline in Mean Diurnal Intraocular Pressure (IOP) at Week 18

Number of Participants With Treatment Emergent Ocular Adverse Events (AEs): Stage I

Number of Participants With Treatment Emergent Ocular Adverse Events (AEs): Stage II

Percentage of Participants Reaching and Maintaining Target Intra Ocular Pressure (IOP): Stage I

Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 (8 AM, 10 AM, 1 PM, 4 PM), 14 (8 AM, 10 AM, 1 PM, 4 PM) and Day 28 (8 AM, 10 AM, 1 PM, 4 PM): Stage II

Change From Baseline in Mean Diurnal Intra Ocular Pressure (IOP) in Study Eye at Day 14: Stage I

Change From Baseline in Mean Diurnal Intra Ocular Pressure (IOP) in Study Eye at Day 28: Stage II

Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 1 (8 AM), 7 and 14 (8 AM, 10 AM, 1 PM, 4 PM): Stage I

Mean Intra Ocular Pressure (IOP) in Study Eye: Stage II

Mean Intra Ocular Pressure (IOP) in Study Eye: Stage I

Percentage of Participants Reaching and Maintaining Target Intra Ocular Pressure (IOP): Stage II

Outflow Facility

Intraocular Pressure

Central Corneal Thickness

Blood Pressure

Aqueous Flow

Episcleral Venous Pressure

Anterior Chamber Volume

Uvescleral Outflow

Change From Baseline Mean Diurnal Intraocular Pressure (IOP) in the Study Eye on Day 28

Change From Baseline in Mean Intraocular Pressure (IOP) at Specific Time Points on Day 14 and Day 28

Target IOP

Percentage of Patients With Corneal Fluorescein Staining Score = 0

Mean Change at Day 90 From Baseline (Day 0) in Ocular Surface Disease Index (OSDI) Score

The Extent of Latanoprost, Bimatoprost and Travoprost Induced Periocular Skin Hyperpigmentation Over a One Year Time Course in Newly Diagnosed Primary Open Angle and Ocular Hypertension Patients.

Mean Change at 12 Weeks (Day 84) From Baseline (Day 0) in Tear Film Break Up Time (TBUT)

Mean Change at 12 Weeks (Day 84) From Baseline (Day 0) in Ocular Surface Disease Index (OSDI) Score

Change From Baseline in Bilateral Intraocular Pressure (IOP) at One Year

Reduction From Baseline in Mean IOP at Week 12 (Observed)

Reduction From Baseline in Mean IOP at Week 12, Last Observation Carried Forward (LOCF)

Reduction From Baseline in Mean IOP at Week 4

Mean IOP at Week 12

Mean IOP at Baseline

Mean IOP at Week 1

Mean IOP at Week 4

Percentage of Participants Discontinuing Therapy Due to a Drug-related Adverse Experience

Intervention	Participants (Count of Participants)
	18 mmHg or lower	16 mmHg or lower	14 mmHg or lower
0.005% Latanoprost	9	3	2
PF-0318 0.006%	9	4	0
PF-0318 0.024%	11	2	1
PF-0318 0.04%	13	3	0

Intervention	Lab* (Mean)
	Upper Lid	Lower Lid	Cheek/Face
Lumigan	-0.90	-0.37	0.30
Travatan	-0.90	0.17	0.51
Xalatan	-1.42	0.48	0.55

Intervention	Millimeters of mercury (mmHg) (Mean)
	Baseline	Change from Baseline at 1 Year
Lumigan®	20.8	-4.8
Travatan®	20.3	-4.3
Xalatan®	20.6	-4.3

Intervention	seconds (Mean)
	1 month	2 months
Currently on Xalatan	-0.59	0.27
New to Meds	-0.86	-2.00

Intervention	Millimeters of mercury (mm Hg) (Mean)
Fixed Combination of Brimonidine Tartrate 0.2%/Timolol Maleate	17.75
Latanoprost 0.005% Ophthalmic Solution	17.90

Intervention	mmHg (Mean)
	Baseline (Day -8): 4 PM	Change at Day 14: 4 PM
Taprenepag+Latanoprost	18.56	5.79
Taprenepag+Latanoprost Vehicle	17.68	4.50

Intervention	mmHg (Mean)
	Baseline (Day -8): 6 PM	Change at Day 14: 6 PM
Taprenepag+Latanoprost	19.10	6.42
Taprenepag+Latanoprost Vehicle	17.29	3.95

Intervention	mmHg (Mean)
	Baseline (Day -8) : 8 AM	Change at Day 14: 8 AM
Taprenepag+Latanoprost	22.77	5.00
Taprenepag+Latanoprost Vehicle	22.41	3.79

Intervention	mmHg (Mean)
	Baseline (Day -8) for Day 14 : 8 PM	Change at Day 14: 8 PM
Taprenepag+Latanoprost	18.58	6.44
Taprenepag+Latanoprost Vehicle	16.66	3.30

Intervention	mmHg (Mean)
	Baseline (Day -7) : 4 AM	Change at Day 15: 4 AM
Taprenepag+Latanoprost	16.77	4.31
Taprenepag+Latanoprost Vehicle	16.66	4.39